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Like all organisms on earth, bacteria must adapt to changes in their environment 
to survive. Thus, discovering bacterial adaptations reveals the tools bacteria use to be 
successful. Identifying how pathogenic bacteria adapt during infections can consequently 
identify the tools bacteria use to cause disease, and therapy design can then consider 
inhibiting these tools to treat or prevent infections. Here, the ways in which two 
worldwide human intestinal pathogens, Campylobacter jejuni and Enterotoxigenic E. coli 
(ETEC), adapt to the human host during infections are explored. Bacteria were studied 
directly in infected samples from controlled human infection models.  In C. jejuni, 
genetic adaptations that were selected for during acute and persistent human infections 
identified the role of a previously uncharacterized flagellar modification gene during 
persistence.  In ETEC, the bacteria’s ability to sense oxygen was linked to global 
virulence gene expression in human infection samples as well as biofilm formation. As 
environmental ETEC biofilms are associated with seasonal ETEC epidemics, oxygen 
sensing likely contributes to human infection inside and outside of the host. Together, 
these data demonstrate the scope of pathogen adaptation during infections, identified new 
targetable virulence factors, and can thus aid the design of new therapies. 
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Chapter 1: Introduction 
1.1 OVERVIEW 
Bacterial intestinal infections are an unparalleled burden on humanity. Billions of 
days of human productivity are lost annually due to symptomatic intestinal disease1. The 
most prominent symptom of bacterial intestinal infections is diarrhea, and profuse 
diarrhea can lead to dehydration and death, particularly in children of low resource 
areas1–3. This dissertation focuses on two major global intestinal pathogens, 
Campylobacter jejuni and Enterotoxigenic Escherichia coli (ETEC), which were first 
identified as causes of infectious diarrhea within a year of each other in the early 1970s4,5. 
Chapter 1 provides background information about these Gram-negative bacteria and our 
continued need to better understand how they cause human disease. One approach to 
understanding disease development is to study the bacterial pathogens directly in infected 
human samples6–9, and this is also discussed in Chapter 1.  In particular, the utility of 
characterizing bacterial adaptation to the host environment is highlighted.   
Rare samples collected from controlled human infection models of C. jejuni and 
ETEC infections were used throughout this work. Chapter 2 demonstrates how C. jejuni 
adapts to the human host by using high-throughput nucleic acid sequencing for genomic 
and transcriptomic analyses.  These data revealed new insight into how C. jejuni causes 
human disease along with new therapeutic targets.  Chapter 3 demonstrates how ETEC 
senses a hallmark of the intestinal environment to regulate virulence factor expression 
during human infections.  Together, these data are discussed in Chapter 4 for their 
contribution to understanding bacterial adaptation during human infection.  Finally, the 
methods used throughout this work, along with cited material, are provided.   
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1.2 CAMPYLOBACTER JEJUNI: A ZOONOTIC PATHOGEN OF THE INTESTINAL TRACT  
1.2.1 Impact and Sources of C. jejuni Infections 
Campylobacter jejuni is spiral-shaped, Gram-negative bacteria that was isolated 
from human feces and identified to be a cause of human intestinal infection in 19725.  It 
is currently the leading cause of bacterial gastroenteritis worldwide and causes 
approximately 1 million infections in North America annually10.  
Symptoms of C. jejuni infection vary widely between patients - from 
asymptomatic colonization to dysentery and bloody diarrhea. Fever and severe abdominal 
cramps are common. A standard presentation of C. jejuni infection can start with fever, 
cramps, and headache before bouts of diarrhea begin that may continue for 5-7 days. 
Typically, infections are self-limiting and do not require antibiotic treatment. Although, 
approximately 15% of gastroenteritis hospitalizations are due to C. jejuni infection10.  
C. jejuni infections are almost exclusively caused by ingestion of contaminated 
food or water. C. jejuni is a commensal bacterium in the intestines of wild and 
domesticated birds - most notably in chickens – and ingestion of contaminated poultry 
products is a major source of C. jejuni infections2,11.   Other livestock, including cattle 
and sheep, can also be seemingly asymptomatically colonized by C. jejuni. Therefore, 
contaminated milk can also be a source of infection12. In high-resource areas, ingestion of 
contaminated and inappropriately prepared poultry meat is the leading cause of C. jejuni 
infection10.  In low-resource areas, contaminated milk, recreational waters, or exposure to 
bird/animal droppings in the environment are major sources of infection2,13.  
Observation of a spiral shaped bacterium associated with Vibrio cholerae-like 
diarrhea in children were reported in the 19th century, however the organism could not be 
cultured14.  Similar observations were attributed to “Vibrio-like” bacteria in later cases, 
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until the bacteria was finally cultured from the feces of a human patient in 19725.  The 
patient had a fever and diarrhea and it was presumed an intestinal pathogen had become 
septicemic. Filtering the patient’s feces and incubating the filtrate on solid medium in 
low-oxygen conditions enabled C. jejuni to be cultivable, and it was identified in both the 
diarrhea and the blood stream of the patient.  
In the laboratory, C. jejuni is fastidious, with a sensitivity to refrigeration and 
freezing, atmospheric concentrations of oxygen, and is asaccharolytic, so standard 
carbohydrates energy sources for use in vitro are not effective15,16. This likely explains 
why previous culturing attempts had failed.  This fastidiousness is seemingly at odds with 
the widespread incidence of C. jejuni infections and understanding this discrepancy is an 
active area of research17.   
Infrequent yet serious extra-intestinal complications can also arise. C. jejuni 
intestinal infections can lead to septicemia, as C. jejuni can be isolated from blood and 
can pose a risk to the health of a fetus in pregnant women18. Reactive arthritis of 
autoimmune origin can also occur which presents as painful and stiff joints which limit 
patient mobility19. Sometimes this presents before diarrhea occurs and the exact C. jejuni 
factors that induce this arthritis are yet to be determined.  
C. jejuni infection also can also induce another autoimmune disorder, called 
Guillain-Barré Syndrome (GBS)20, which is a life-threatening paralysis that requires 
immediate medical intervention. GBS results from anti-C. jejuni antibodies that cross-
react with surface exposed sugars found on nerve cells21. The resulting autoimmune 
response degrades neurons causing a progressive paralysis which can quickly lead to 
diaphragm dysfunction and suffocation. Immunosuppressants can halt the response and 
eventually allow for recovery22.  The cross-reactive antibodies are generated by immune 
recognition of sugars on C. jeuni lipooligsaccharide that structurally mimic human 
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gangliosides23. These antibodies therefore recognize both C. jejuni and neuron surface 
structures.  A naturally occurring C. jejuni strain, CG8421, was isolated from a patient in 
Thailand which is missing the genetic loci that encode for the production of the cross-
reacting sugars24. CG8421 was therefore approved for use in controlled human infection 
models of infection as the risk of potentially lethal GBS was eliminated. Humans infected 
with CG8421 produce a typical range of symptomatic disease, ranging from lose stools to 
severe bloody diarrhea with high fever and abdominal cramping24.  
Besides the high incidence of infection in high-resource areas, children in low-
resource areas are at risk of lethal or permanently debilitating infections13.  Recent 
exhaustive global surveys have associated Campylobacter infections during the first year 
of life with stunted growth periods2.  Growth stunting is thought to occur due to 
malnutrition during infection and is associated with lifelong physical and cognitive 
deficits.  Consequently, what is sometimes considered to be a nuisance bout of diarrhea in 
high-resource areas can be a devastating, life-changing event in low-resource areas.  
1.2.2 C. jejuni Colonization Factors 
The first C. jejui genome sequence was surprising for a number of reasons -  most 
notably for revealing a complete lack of pathogen-defining toxins25. The genome was also 
surprisingly small (about 1/3 the size of the ETEC genome) and harbored seemingly no 
unique or notable secreted virulence factors.  For instance, there are no homologs to 
enterotoxins, cholera toxin, or shiga toxin in the genome. Another surprising feature was 
over 25 phase variable regions where homopolynucleotide C/G tracts were found 
throughout the genome. These phase variable regions are prone to insertion/deletion 
mutations and consequently introduces astounding genetic and phenotypic heterogeneity 
in a C. jejuni population26.  
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Overall, there is seemingly minimal mechanistic understanding of C. jejuni 
human pathogenesis when compared to other intestinal pathogens that have clearly 
defined essential virulence factors. It is believed that despite our knowledge of the 
genome, there are likely conserved, defining virulence factors yet to be discovered in C. 
jejuni27.  That notwithstanding, prominently accepted C. jejuni colonization factors and 
phase variation’s contribution to disease are covered in the remaining sections of this 
chapter.  
1.2.2.1 Motility, Adherence, and invasion 
Unlike other intestinal pathogens that rely on characteristic and essential adhesins 
and secreted toxins for colonization, major factors dictating C. jejuni colonization are 
considered to be basic observations of motility, adherence, and invasion. It is an invasive 
pathogen, although mechanisms of adhesion and invasion into host cells in vivo are not 
well understood.  After ingestion C. jejuni uses flagellar-based motility to enter the 
mucus layer that protects the small intestine epithelium, and consequently 
adheres/associates to the host epithelium28.  After colonizing the small intestine, C. jejuni 
can also colonize the colon which is likely to origin of blood when bloody diarrhea 
symptoms present29.    
In vitro, C. jejuni can be seen adhering to and invading epithelial cells. JlpA30,31 
and CadF32 are two C. jejuni surface exposed proteins have been shown to bind to host 
surface/extracellular proteins (Hsp90 and fibronectic, respectively) to mediate adhesion 
in vitro. After adhesion C. jejuni can invade host cells, although mechanisms of invasion 
are murky.  A group of proteins called Campylobacter invasion antigens (Cia) have been 
identified that enhance the rate of C. jejuni invasion33, and CiaB is internalized into host 
cells via unknown mechanisms33.  
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 Some strains are more invasive than others, indicating a role for distinct genetic 
loci beckoning the discovery of new invasins. A gene called cipA was identified in 
unbiased screens to be associated with strains that are more invasive and with strains that 
caused more severe human disease34.  Although until this work presented in Chapter 2, 
the biochemical function of CipA was unknown.  
Interestingly, C. jejuni lacks type III secretion mechanisms that other invasive 
bacteria use to secrete invasins.  However, it was reported that C. jejuni surprisingly uses 
the flagellar apparatus to secrete proteins35, possibly in lieu of a type III secretin system. 
These secreted proteins include the Cia proteins along with other non-flagellar proteins36.  
For instance, the C. jejuni specific protein FspA (flagella secreted protein A) is secreted 
through the flagellar filament, and when added exogenously onto epithelial cells in vitro, 
induces host cell apoptosis.  However, the role of this secretion mechanism or these 
secreted proteins in mammalian infections is unresolved.  
1.2.2.2 Cytolethal Distending Toxin 
The heterotrimeric AB toxin, cytolethal distending toxin (CDT), is found in 
multiple pathogenic Proteobacteria, including Shigella dysenteria, E. coli, Salmonella 
enterica, and C. jejuni37. The CdtB subunit of the CdtABC holotoxin uses DNAse activity 
to arrest eukaryotic cells in G2/M of the cell cycle38.  This inhibition results in large, 
distended cells which give the toxin its name.   
Because of work done on CDT in the context of other pathogens, CDT is 
inadvertently the most well characterized toxin in C. jejuni39. However, the role of CDT 
in symptomatic human disease or chicken colonization is unclear.  Notably, symptomatic 
human disease can be caused by CDT-negative C. jejuni strains40, and its role in the 
native host is unclear as chickens do not make antibodies against CDT40,41.  Further, other 
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pathogens that harbor CDT do not necessarily use it as an essential colonization factor42, 
suggesting a limited role in C. jejuni as well.   
1.2.2.3 Iron Acquisition  
Iron is a vital cofactor for all bacteria, and host organisms have numerous 
mechanisms for sequestering iron as a form of nutritional immunity43,44.  To increase the 
efficiency of iron acquisition, many bacteria secrete ferric iron chelating proteins, called 
siderophores45. After secretion, a surface-exposed siderophore importer is used to import 
iron-bound siderophores to harvest iron from the environment. Siderophores tend to be 
strain-specific so a bacterial species can preferentially and efficiently uptake its own 
siderophore to harvest iron in a competitive environment46–49. Interestingly, C. jejuni does 
not harbor a siderophore biosynthesis pathway, but does encode a promiscuous 
siderophore importer than can uptake siderophores made by other bacteria50. The 
importer, CfrA, is an important chicken colonization factor, and therefore microbiome 
derived siderophores contribute to C. jejuni success in vivo.  
1.2.3 Genetic Phase Variation in C. jejuni 
Phase variation is a population-level adaptation mechanism that some bacteria, 
including C. jejuni, rely on to be successful in diverse environments51–53. In C. jejuni, 
phase variation is dictated by relatively high-frequency small nucleotide 
insertion/deletion mutations in homopolynucleotide tracts throughout the genome25.  
These polymorphisms disrupt promoter regions or open reading frames to genetically 
turn a gene functionally “on” or “off”. Considering approximately 30 of these phase 
variable tracts exist in a C. jejuni genome, there are over a billion possible combinations 
of on/off phase variations. This represents an incredible amount of standing genetic (and 
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likely phenotypic) heterogeneity within a single C. jejuni population.  Besides phase 
variation, standard small nucleotide polymorphisms (SNPs) that naturally occur during 
bacterial replication are also independently contributing to genetic variation within C. 
jejuni populations. Presumably a subpopulation of cells will intrinsically have the 
appropriate combination of genes in an on or off phase to succeed after a transition into a 
new, harsh environment54. In this way the standing genetic diversity in a C. jejuni 
population predisposes subpopulations to be successful when the population is exposed to 
a new environment – for example when transitioning from a piece of chicken into the 
mammalian intestinal tract52. Bacterial cells with genetic variations that increase fitness in 
the new environment will propagate more successfully and therefore become the major 
genotype of the transitioned population.  
 Approximately 30 homopolynucleotide tracts made up of between approximately 
5-12 repeated C/G nucleotides are found throughout the C. jejuni CG8421 genome. This 
nucleotide repetition is difficult for the cell to accurately replicate during division and 
leads to a higher frequency of slip-strand nucleotide insertion/deletion mutations within 
these tracts.  Exhaustive work has identified the frequency of a mutation occurring in 
phase variable tracts to be once in ~300-3000 replications, depending on the tract26. 
Generally, the farther a tract length is from 7 nucleotides long, the more likely it is to 
have an altered tract length after division, and the more likely the tract length will 
become closer to 7 nucleotide long. Interestingly, in eukaryotic cells, repeated nucleotide 
tracts are thought to theoretically increase in length indefinitely, although in C. jejuni 
they rarely exceed 12 nucleotides and tend to regress towards 7 nucleotides in length on 
average.  The mechanisms dictating these tract length boundaries in C. jejuni are unclear, 
and otherwise, C. jejuni has normal rates of genomic mutation and DNA repair fidelity54.  
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Notable phase variable genes include genes involved in capsule and LOS 
structures and flagella modification genes55. The role of phase variation in these genes is 
generally murky because the nuances of surfaces structures are can be difficult to 
identify.  “Locking” a gene into a particular phase to study takes considerable genetic 
work, and does not control for phase variability of genes that may provide a redundant 
function. 
Although phase variation frequency in a given tract generally requires hundreds 
of replications to naturally occur under constant environmental conditions53, exposure to 
stressors can immediately select for successful variants and eliminate vulnerable 
variants52,54.  In this way exposure to a new environment can almost immediately 
eliminate particular phase variants from a population without the need for growth and 
replication, and congruently, this would immediately increase the frequency of successful 
phase variants within that population.  This dichotomy can be applied to genomic 
sequencing of C. jejuni populations before and after exposure to a stressor. For instance, 
the genome of an inoculum population of C. jejuni can be sequenced, and the frequency 
of every phase variation (or any other polymorphism for that matter) can be identified52.  
The inoculum could then be used in animal colonization model, and post-infection isolate 
populations can be sequenced.  Genetic variations that greatly increased in frequency 
during infection represent genes that are contributing to infection and therefore provide 
insight into the tools C. jejuni is relying on to be successful in the host. Similar 
experiments have been done in chicken and mouse models of colonization to characterize 
the extent of phase variation in vivo26,52.  In the work described in Chapter 2, this 
approach is used to identify C. jejuni colonization factors in human infections. 
Importantly, C. jejuni infections can be persistent, and no animal models have been 
characterized to show similar relapsing, recrudescent infections.  Therefore, a human 
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challenge model is the only available way to study the factors that contribute to C. jejuni 
persistence in mammals.   
1.2.4 Therapies for C. jejuni infection 
C. jejuni infections are typically self-limiting in immunocompetent hosts56. 
Rehydration is recommended while experiencing symptoms, and if hospitalized, 
intravenous rehydration can be prescribed.  Antibiotics can be prescribed for 
immunocompromised individuals, or individuals who experience rare systemic disease57–
59.  Severe symptoms, particularly high fever (> 104°F), can also warrant antibiotics24. 
Although antibiotics will quickly eliminate detectable C. jejuni in stool, they do 
not provide relief from the severity/duration of the diarrhea nor abdominal cramping 
symptoms.  Erythromycin is commonly prescribed. Antimotility agents, such as 
Imodium©, are not recommended as they can make symptoms worse and are associated 
with a higher risk or mortality59.  This may be due to a decreased rate of eliminating the 
bacteria from the intestine via excretion.  
Prophylactic antibiotic treatments that typically work for other intestinal 
pathogens are ineffective for C. jejuni60,61.  Most notably is the failure of Rifaximin to 
limit Campylobacteriosis in a human challenge model. Rifaximin is a poorly absorbed 
broad-spectrum antibiotic that is therefore ideal for treating gastroenteritis. Rifaximin 
prevents shigellosis60 in a human challenge model and has preventive activity against E. 
coli gastroenteritis, however did not prevent Campylobacteriosis61.   
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1.2.4.1 A Controlled Human and Non-human Primate Challenge Models to Test New 
Therapies 
In a controlled human infection model, a single large scale inoculum is produced 
and ingested simultaneously by a group of naïve human volunteers24.  The inoculum is 
typically a resuspension of bacteria grown on solid-medium, and is a combination of 
multiple growths and therefore not derived from a single colony.  Non-human primates 
are also susceptible to most human enteric pathogens, and can be challenged in a similar 
way62. Humans are often given bicarbonate solutions to ingest to neutralize bactericidal 
stomach acid24, and non-human primates may require combinatorial neutralization 
treatments (such as addition of ranitidine and/or use of proprietary formulations like 
CeraVax©) for optimal colonization62.  As bacteria isolated from human infections are 
typically used, a lower infectious dose is required to produce symptomatic disease in 
humans than in non-human primates.  For instance, 5x105 bacteria are used to produce 
Campylobacteriosis in humans, but the new-world primate Aotus nancymaae requires 
5x1011  to cause disease.  Non-human primates recapitulate human disease better than any 
non-human primate model, particularly considering the native microbiota do not need 
altered before challenge62. However, the dosage is larger than what would naturally be 
encountered. 
C. jejuni strain CG8421 has been characterized for use in controlled human and 
non-human primate infection challenges24. Its utility in these models comes from a lack 
of GBS-generating LOS structures, so human volunteers are not at risk for the life-
threating autoimmune disorder.   Azithromycin and ciprofloxacin are used in conjunction 
to eliminate C. jejuni at the end of a human challenge model or if a volunteer experiences 
severe enough disease to warrant early intervention. These antibiotics were chosen 
because they effectively kill C. jejuni in vitro and in vivo at non-toxic levels to the host, 
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and also accumulate to high concentrations intracellular to be sure invasive bacteria can 
be reached63.   
1.2.4.2 Recrudescent C. jejuni Infections in Humans 
C. jejuni has the potential to persist in humans beyond the duration of acute 
disease.  Relapsing - so called “recrudescent” infections – have become a new and 
significant focus in the Campylobacter field2,9. Campylobacter’s fastidiousness makes 
isolation from humans more burdensome than for other pathogens, particularly in low 
resource clinics.  This results in an under representation of Campylobacteriosis cases 
worldwide, and failed detection of recurrent Campylobacter infections2.   
However, using multiple diagnostic tests to detect Campylobacter in children of 
low-resource areas, a groundbreaking 2016 study demonstrated the shockingly high rate 
of Campylobacter infection and persistence in children2.  Out of 2087 children examined 
across South America, Africa, the Middle East, and South/Southeast Asia, 84.7% of 
children had a Campylobacter positive stool by 1 year of age.  Notably, high 
campylobacter burdens were associated with periods of growth stunting within the first 
year, and growth stunting is strongly correlated with lifelong physical and/or cogitative 
deficits.   
Remarkably, 28% of children in low-resource areas were persistently infected by 
Campylobacter during the first year of life, some with asymptomatic colonization and/or 
potentially continuous re-infection. In adults, the incidence or existence of recrudescent 
infection was controversial until recently.  The success and thoroughness of recent 
Campylobacter human challenge models revealed that almost 20% of adults can present 
with recrudescent infections61. Relapse infections occur about two weeks after the initial 
acute infection subsides, even if azithromycin and ciprofloxacin antibiotic treatments had 
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successfully eliminated detectable C. jejuni from the stool. The host and pathogen factors 
that contribute to persistence have not been elucidated, and to date, no small animal 
models accurate recapitulate human recrudescence.  Therefore, human models of 
infection are the only method to study C. jejuni persistence in mammals. The work 
presented in Chapter 2 identifies bacterial factor that are selected for in human 
recrudescent infection and elucidates the role of the host in disease severity.   
1.2.4.3 Vaccine Development  
Currently there are no vaccines available to prevent C. jejuni infections. However, 
repeat exposures to homologous C. jejuni strains offers immunity to future challenges, 
indicating a Campylobacter vaccine is feasible in principle29. However, as described 
above, our limited understanding of C. jejuni pathogenesis and persistence makes rational 
design of vaccines difficult64. Further, standard whole cell or outer membrane vesicle 
vaccine approaches are concerning given the known risk of generating GBS. However, 
capsular polysaccharide (CPS) structures do not feature ganglioside mimics, and 
therefore CPS is an attractive antigen to be used in a vaccine62,65. CPS on C. jejuni also 
supports the cell invasion process in vitro, and anti-CPS antibodies can hinder this 
process, indicating a potentially efficacy of anti-CPS vaccines66.  Generally, though, 
polysaccharides are poorly immunogenic, and therefore CPS-conjugate vaccines are 
being pursued65.  A drawback to these conjugate vaccines are the prevalence of different 
C. jejuni capsule serotypes, with approximately 60 different serotypes identified.  
However, a multivalent vaccine currently in clinical trials could protect against over 30% 
of known serotypes, and at least demonstrate the efficacy of such conjugate vaccine 
approaches in C. jejuni.   
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Therapy development would benefit from knowledge of additional targets that 
contribute to human infection.  Currently, chicken colonization models (a native host) are 
used to identify colonization factors, but the zoonotic lifestyle of Campylobacter makes 
extrapolating these data to human infection perilous. The work described in Chapter 2 
identifies genetic factors that are selected for during human disease, along with genes that 
are highly expressed during human infection.  Rational therapy design may benefit from 
considering these factors when choosing antigens for future vaccines. 
1.3 ENTEROTOXIGENIC E. COLI (ETEC): A GLOBAL CAUSE OF TRAVELER’S DIARRHEA  
1.3.1 Impact and Sources of ETEC Infections 
Enterotoxigenic Escherichia coli (ETEC) is a gram-negative bacterial intestinal 
pathogen that infects 200 million people every year1,3,67. It was originally described in the 
early 1970s and infection typically results in acute watery diarrhea which can potentially 
result in lethal dehydration4,68–70. Assessments to define diarrhea vary amongst clinicians, 
however it is common to consider three loose stools within 24 hours to be diarrhea. 
Additional symptoms of ETEC infection can include abdominal cramping and vomiting4. 
However, vomiting is rare compared to the frequency of diarrhea-associated symptoms. 
ETEC diarrhea is typically an acute, profuse, watery diarrhea and therefore is often 
described as “cholera-like”4,71.  Unsurprisingly, then, is the presence of a cholera-like 
toxin in some strains of ETEC69. These virulence factors are discussed in Chapter 1.3.2.   
Classic ETEC symptoms of acute diarrhea often last between 4 and 14 days.  
These symptoms are often debilitating, leading to low productivity during illness72. A 
2010 study determined that ETEC infections account for an annual loss of 6.8 million 
disability-adjusted life years of human productivity72.   Further, pervasive ETEC diarrhea 
occurs in some patients and can last 30 days or more and require treatment with 
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antibiotics73,74.   Given an approximation that the average duration of ETEC illness is 7 
days, and considering 200 million people every year are infected by ETEC, one can 
estimate that over 1 billion days of human productivity are lost annually to ETEC 
infections.  This is a loss of approximately 2.7 million years’ worth of societal output – 
inarguably a devastating loss - and a strong motivator to better understand and treat 
ETEC infections.  
 Although infection of adults in high-resource areas is rarely deadly, young 
children and infants in low resources areas are at a high risk of death due to their naïve 
immune system and propensity for rapid dehydration75.  The duration of diarrhea can also 
result in malnutrition in infants which is associated with stunted growth periods. Notably, 
similar stunted growth phases during the first year of life in low-resource areas is 
associated with life long physical and/or cognitive deficits2,72.  
Low-resource areas throughout the world, including most countries in Latin 
America, Africa, south/southeast Asia, have the largest burden of ETEC infection1,72. 
ETEC infections are considerably rarer in high-resource areas like the United States and 
Europe which utilize effective and widespread public water treatment. Therefore, food-
borne outbreaks are the most typical source of rare ETEC infections in these developed 
regions74,76.  
Overall, children in low-resource areas account for most ETEC infections, and 
those that survive gain natural immunity to their local ETEC strain(s)75. International 
travelers to endemic countries are also at extreme risk of ETEC infection with an 
estimated 10 million becoming ill each year.  Accordingly, as many as two thirds of 
visitors to tourist attractions in endemic areas have been reported to contract ETEC 
infections77. Although boiling water and eating cooked food can decrease the risk of 
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contracting ETEC, it can be difficult for travelers to prepare their own food or to properly 
ensure their purchased food and drink was appropriately prepared.   
The United States military is also burdened by ETEC infection, as an estimated 
25-50 percent of troops deployed in developing countries will have ETEC-associated 
diarrhea during combat or training78,79.  As reported by Bloomberg magazine in December 
2015, the military estimates they lose over 1 million days of soldier activity due to 
diarrheal infections each year.   This has spurred significant research endeavors within 
the United States Navy Medical Research Center to better understand ETEC infections80.  
Their efforts to develop ETEC vaccines, along with the treatment endeavors of other 
groups, in detailed in Chapter 1.3.4.   
ETEC infections are difficult to prevent in endemic areas because contaminated 
water is a major source of ETEC. When water purification resources are inadequate it can 
be difficult to contain ETEC contamination, and congruently, surface waters in afflicted 
areas are frequently found to contain ETEC81–83. This is exacerbated by the vast amount 
of infected diarrhea produced by afflicted humans which can easily contaminate 
environmental sources of water. When this contaminated water is used recreationally, 
consumed as drinking water, or used to wash produce and dishes, infection is almost 
certain in naïve consumers81.  
ETEC endemics are often seasonal, likely due to people associating with 
contaminated recreational waters more frequently in warmer seasons76,84.  However, 
ETEC can also be found indoors. The presence of ETEC biofilms within the indoor water 
reservoirs of homes in low-resources areas are associated with seasonal epidemics84.  
ETEC infections are frequently referred to as “travelers’ diarrhea,” and certainly it 
is a leading cause of such diarrhea.  However, it is also a deadly infection in children, and 
infants that do survive may have lifelong physical and/or cognitive deficits as a result1,2.  
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Although survivors of ETEC infection gain a natural immunity to their local ETEC strain, 
this often does not provide protection to ETEC strains found in other areas. Therefore, 
traveling to another region with a different endemic strain can lead to infection, and 
immunogenicity to ETEC is discussed in Chapter 1.3.4.  The burden on travelers extends 
to military personnel who are deployed around the world, and infections in soldiers has 
spurred the Navy in investigate new ETEC vaccines used in human clinical trials78–80.  
Samples collected from these human challenges are used in this dissertation work and are 
described in Chapter 3. 
1.3.2 ETEC Virulence Factors 
ETEC can use a trio of plasmid-borne “classical” virulence factors to cause 
disease in mammals70,85,86.  Bacterial adhesion to host cells is a required colonization 
factor for almost all bacterial pathogens. Adhesins are surface exposed pilus-like 
structures that allow bacteria to physically adhere to surfaces or host cells.  At least one 
adhesin is used by ETEC to adhere to the intestinal epithelium to cause symptomatic 
disease87. This allows for 1) the bacteria to attach and associate with the host intestinal 
epithelium 2) ensure affective delivery of secreted toxins directly to host epithelial cells 
3) resist the flushing action of the diarrhea that is induced by these toxins.  ETEC 
adhesion are discussed in Chapter 1.3.2.1. 
 Beyond adhesins, ETEC is defined by the enterotoxin genes it harbors. 
Enterotoxins are proteinaceous secreted toxins that induce an efflux of water from the 
cytoplasm of host epithelial cells into the lumen of the intestine68,69. This efflux of water 
is the source of the characteristic watery diarrhea.   The prototypical ETEC strain 
H10407, which was originally isolated from an adult with cholera-like symptoms in 
197385, harbors both a heat-labile enterotoxin and two heat-stable enterotoxin homologs 
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and is examined in this dissertation.  Enterotoxigenic heat-stable (ST) and heat-labile 
(LT) toxins, although structurally and enzymatically different88,89, both induce diarrhea.  
Despite many ETEC isolates harboring multiple enterotoxins90,91, only one is required to 
induce symptomatic disease when accompanied by a functional adhesin86.  These 
enterotoxins are described in more detail in Chapter 1.3.2.2.  
These classical ETEC virulence factors (adhesins and enterotoxins) are found on 
so-called virulence plasmids within ETEC strains85,92.  The number of plasmids and 
virulence factors varies per ETEC isolate, however the prototypical ETEC strain H10407 
harbors 4 virulence plasmids (p948, p666, p52, p58) and four classical virulence factor 
homologs (an adhesin called CFA/I, two ST homologs, and LT)93.  
1.3.2.1 ETEC Adhesins 
Approximately 25 different adhesins have been identified in ETEC strains 
isolated from humans around the world.  However, up to 50% of clinical isolates test 
negative for any known adhesin type despite having adhesive ability in vitro and causing 
human disease94.  This indicates the requirement for adhesion can be fulfilled by a variety 
of apparatuses and that significantly more investigation is warranted into adhesin 
diversity in ETEC.  This dissertation will focus on the prototypical adhesin, Colonization 
Factor Antigen I (CFA).  
The CFA adhesin is found in 30-40% of ETEC isolates, including in strain 
H10407, and is well characterized75. In H10407, the operon cfaABCE encodes the main 
structural subunit of the CFA adhesive pilus (CfaB), the adhesive tip found at the end of 
the pilus (CfaE), and the outer membrane usher and periplasmic chaperone proteins 
(CfaC and CfaA, respectively) which build the extracellular pilus87,95.  The structures of 
CfaB and CfaE has been determined – both of which are barrel shaped proteins with 7-
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stranded β-sandwich folds of the Ig-family87. Surprisingly, there is minimal contact 
between CfaE and CfaB, with only 4 hydrogen bonds enabling CfaE association with the 
last CfaB subunit of the pilus.   
A eukaryotic membrane receptor for CfaE-mediated adhesion has not been 
identified. However, ETEC that infect pigs harbor porcine-specific adhesins96 which have 
known glycoprotein receptors97. Surface exposed mucin-type glycoprotein (IMTGP) on 
porcine brush border intestinal epithelial cells is bound by the porcine ETEC adhesin 
K88.  Pigs that do not produce this receptor (IMTGP-) are less susceptible to symptomatic 
disease when challenged with a K88+ ETEC strain than IMTGP+ pigs98.  Interestingly, 
porcine ETEC strains that rely on the K88 adhesin do not appear to cause disease in 
humans, although porcine homologs of ST and LT are found in human ETEC isolates 
that cause disease99.   
The cfa operon is found on the ETEC H10407 virulence plasmid p999, along with 
the regulator of the operon, cfaD100,101.  cfaD is generally considered constitutively 
expressed and is a DNA binding protein which activates expression of the cfaABCE 
operon by binding to its promoter region102.  Although CfaD is unique to ETEC, it is part 
of the AraC-family of virulence transcriptional regulators which are found in many 
pathogens and bind asymmetrically to AT-rich sequences in promoter regions of 
virulence genes103,104.  This binding can displace the repressive binding of the histone-like 
nucleoid-structuring protein (H-NS) at these promoter regions102.   
A rich media that was used to grow ETEC soon after its discovery ensures robust 
expression of the CFA adhesin in strain H10407, and therefore has the namesake “CFA 
media” and is now a standard growth media when working with ETEC in vitro80. 
Expression of cfaD, and therefore expression of the cfa operon, was recently shown to be 
increased by exogenously added bicarbonate (HCO3)100. Bicarbonate has been shown to 
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influence virulence factor expression in a number of pathogens, likely due to providing a 
more accurate approximation of in vivo CO2 concentrations during laboratory culture 
growth105,106. Beyond this work, however, little is known about the regulation of cfaD 
expression.  
Beyond activating expression of the cfa operon, CfaD activates expression of 
itself, along with a few “non-classical” virulence-associated genes which are discussed in 
Chapter 3107. It is worth explicitly noting, however,  that cfaD does not regulate the 
expression of either ST or LT100, which are discussed in the following section. 
1.3.2.2 Secreted Toxins 
H10407 harbors both heat-stable (ST) and heat-labile (LT) enterotoxins93.  The  
genes sta1 and sta2 are two ST enterotoxin homologs found on virulence plasmids p666 
and p948 respectively92.   Sta1 is a secreted 18 amino acid peptide that is also found in 
ETEC strains associated with porcine infection, and therefore is sometimes called STp.  
Sta2 is a secreted 19 amino acid peptide is that exclusively found in ETEC isolated from 
human infections and therefore is sometimes called STh. As both of these toxins are 
discussed in the context of the human isolate H10407 they are referred to as Sta1 and 
Sta2 in this dissertation.  It is not uncommon for ETEC isolates to harbor multiple 
enterotoxins and at least three other STh variants have been described108.   
The Sta genes encode for an initial peptide of 72 amino acids in length which is 
eventually processed to produce a short (about 18 amino acid long) peptide for 
secretion109.  The peptides contain a 19 amino acid pre-region, which is a signal peptide 
for secretion into the periplasm.  This pre-region is cleaved off via signal peptidase.  
Once in the periplasm, disulfide bonds important for toxin function are formed.  Then 
~44 amino acids are cleaved off the n-terminal of the peptide, leaving 19 (Sta2) or 18 
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(Sta1) amino acids that represent the mature, functional, secreted toxins109. Secretion then 
occurs in a TolC-dependent manner.   
In the host, secreted ST toxins bind to the transmembrane guanylyl cyclase C 
receptor (CG-C)110,111 on the brush boarder membrane of epithelial cells.  CG-C plays an 
important role in controlling the fluid content of the intestine by regulating electrolyte 
and associated water efflux into the intestine111.  Binding of ST to the extracellular 
domain of CG-C activates the CG-C intracellular domain to catalyze the production of 
cyclic guanosine monophosphate (cGMP)112.  Elevated levels of intracellular cGMP 
activate cGMP-dependent protein kinase PKGII, which in turn activates a transmembrane 
chloride channel (cystic fibrosis transmembrane conductance regulator, CFTR) via 
phosphorylation112.  Activated CFTR exports chloride ions (Cl-) into the lumen of the 
intestine which at increased concentrations induces an osmotically induced efflux of 
water from host epithelial cells into the lumen113.  
ST-induced cGMP accumulation in host cells can stimulate electrolyte efflux via 
two additional pathways.  The first is by inactivation of phosphodiesterase 3 (PDE3) 
which results in accumulation of intracellular cyclic adenosine monophosphate 
(cAMP)114.  Increased intracellular cAMP concentrations activates protein kinase A 
(PKA) which also stimulates CFTR via phosphorylation to export Cl- into the lumen115. 
Finally, PKA also inhibits a Na+/H+ exchanger membrane channel (NHE3) which imports 
Na+ from the lumen via exchange of H+ export into the lumen116. By inhibiting Na+ 
import into the host cells, the electrolyte concentration in the lumen is further elevated, 
leading to increased osmotic stress that results in water efflux from the cytoplasm into the 
lumen. Notably, CFTR null mice are viable, resistant to ST-induced water efflux in the 
intestine, and resistant to ST+ LT- ETEC colonization117.    
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LT is a hexameric secreted enterotoxin found in both porcine and human ETEC 
isolates89,99. It is an exemplary AB5 toxin, where 5 “B” protein subunits (LTB) and 1 “A” 
protein subunit (LTA) associate make up the functional holotoxin. The genes for LTA 
and LTB are named eltA and eltB in H10407 and are overlapping in an operon (eltAB) on 
virulence plasmid p66693.   It is homologous in structure, function, and nucleotide/amino 
acid sequence to cholera toxin from the intestinal pathogen Vibrio cholerae118.   
Evolutionary sequence analysis estimated E. coli acquired LT via a horizontal 
gene transfer event from V. cholerae approximately 130 million years ago. The eltAB 
operon is approximately 80% homologous to the cholera toxin operon, ctxAB.  This most 
divergent domains between the two toxins are the N-terminal signal peptide sequences 
which target the proteins to the periplasm.  This sequence is cleaved off before secretion 
by signal peptidase and therefore is consistent with a domain that can tolerate sequence 
variation. After reaching the periplasm, LTA and LTB spontaneously oligomerize to 
form LT with appropriate stoichiometry119 and is secreted via the gspC-M type II section 
pathway120. Secreted LT can travel freely in the extracellular milieu, or is also capable of 
associating with bacterial outer membrane (OM) or extracellular outer membrane vesicles 
(OMVs) via interaction with membrane anchored bacterial sugars121.   
Once secreted, LT functions identically to cholera toxin to induce diarrhea. First, 
LT binds to a monosialoganglioside GM1 receptor on the surface of epithelial cells and is 
subsequently endocytosed122.  The LTA subunit then enables ADP-ribosylation of the 
Gsα subunit of the host G-protein in the endoplasmic reticulum123.  This activates G-
protein to activate adenylyl cyclase which cleaves ATP to cAMP. Increased levels of 
intracellular cAMP activates protein kinase A, which results in similar electrolyte 
imbalance via NHE and CFTR as discussed with ST.    The differences in the host 
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response to free LT vs OMV or OM associated LT is currently an active area of 
investigation in ETEC pathogenesis124.  
1.3.4. Available Treatments and Therapy Development for ETEC Infections 
Current Treatments 
Generally, ETEC infections are self-limiting and don’t require antibiotic 
intervention75,125,126.  Hydration with clear liquids is recommended until diarrhea subsides.  
Prophylactic treatment with the antibiotic Rifaximin can be prescribed to at-risk travelers 
who may not be able to tolerate a bout of infectious diarrhea due to other health 
conditions127. Although Rifaximin is an effective prophylactic treatment for E. coli and 
Salmonella infections it is not affective against C. jejuni infections61.  Bismuth 
subsalicylate (Pepto-Bismol©) and anti-intestinal-motility agents (Imodium©) are 
effective at decreasing the number of loose stools and lessening the severity of diarrhea-
associated cramps128. If antibiotic intervention is required in severe cases, azithromycin is 
typically prescribed, as it is also affective against other intestinal pathogens (including C. 
jejuni) and there is low resistance amongst ETEC isolates80.  
Vaccine Development  
Vaccines are a means to induce protective immunity against a pathogen to prevent 
future infections. Travelers to afflicted regions are at high risk for ETEC infection, and 
therefore a vaccine that can provide protection from ETEC infection before traveling is 
an attractive area for therapy development.  ETEC’s classical virulence factors (adhesins, 
LT, and ST) are all highly immunogenic, and host antibodies against these factors 
provide protection in animal models of infection. This explains why after becoming 
infected with a local ETEC strain, reinfection does not occur.  However, ETEC isolates 
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from around the world have shown there is significant diversity amongst virulence 
factors, particularly the adhesins, and this explains why standing immunity to a local 
ETEC strain may not provide protection against a strain from another region of the 
world94.  There is lesser diversity seen amongst ST and LT homologs so they are used 
more frequently as antigens during vaccine development108.   
To overcome the geographic diversity seen in ETEC, the most promising vaccines 
are multivalent.  For example, a vaccine that can induce immunity against the most 
common adhesins seen in ETEC (CFA/I and CS1-6) and LT could provide protection 
against 80% of all known ETEC strains80.  
Controlled human infection models (CHIM) are affective ways of testing the 
efficacy of ETEC vaccines.  In a CHIM, human volunteers simultaneously ingest a 
portion of a lab grown ETEC culture and become infected in a clinical setting.  Using a 
double blinded approach, volunteers can be administered either a test or sham ETEC 
vaccine prior to challenge, and the efficacy of the test vaccine can be determined by 
comparing the severity of diarrhea experienced by volunteers who were given the test 
vaccine vs the sham control vaccine80.   
Recently a human clinical trial and CHIM was preformed to test the efficacy of 
vaccine using CfaE and inactivated LT as the protective antigens (ClinicalTrials.gov 
Identifier: NCT01922856). In the trial, human volunteers were challenged with ETEC 
H10407 after being vaccinated against CfaE/LT or with a control sham vaccine.  The 
results of the trial have yet to be made public, however this dissertation uses samples 
obtained from these volunteers to investigate ETEC directly in human infection samples.  
The CHIM provides a number of advantages to studying ETEC directly in in vivo 
infection samples than collected diarrhea samples from naturally acquired ETEC 
infections.  First, all patients consume a portion of the same inoculum simultaneously.  
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This enables direct comparison of bacteria across infected samples without confounding 
differences between strains or time post-inoculation.  Second, volunteers are pre-screened 
for the naivety to ETEC infections, so confounding pre-existing immunity to the infected 
strain need not be considered. Finally, the H10407 strain used in the recent CHIM is well 
characterized71,80,85,126, including the full genome sequence93 and extensive research on 
virulence factor production and regulation129.  This allows conclusions drawn from this 
study to be immediately considered within the context of decades of previous work.   
1.4 CHARACTERIZING BACTERIAL ADAPTATIONS REVEALS IMPORTANT SURVIVAL 
MECHANISMS 
Organisms must adapt and respond to changes in their environment in order to 
survive. Bacteria are no exception, and bacterial pathogens must be fit to survive in a 
wide range of environmental conditions.   Two major ways bacteria adapt to their 
environment are 1) sensing of important environmental cues and responding to them via 
changes in gene transcription130 or by 2) a genetic response - direct selection for particular 
bacteria that are more fit to survive - which is due to genetically encoded differences 
between bacterial cells131. Each of these adaptation methods, and how we can characterize 
them to reveal the tools bacteria used to survive or cause disease, are discussed below. 
1.4.1 Using Next-generation RNA Sequencing to Characterize Transcriptional 
Adaptive Responses in Bacteria.  
C. jejuni is able to survive in diverse environments - as it survives in mammalian 
intestines, avian intestines, milk, environmental water, in refrigerated conditions and/or 
on raw poultry, and within host cells2,12,132.  It must sense changes between these 
environments and adapt accordingly in order to survive in these diverse conditions.  For 
example, C. jejuni senses bile as a que to promote survival in the intestine133. Bile is an 
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important emulsifier in the intestine and C. jejuni harbors a transcriptional regulator 
named CmeR which is directly bound by bile acids134. In the absence of bile, CmeR binds 
to the promoter regions of over 20 genes and represses their expression130.  The CmeR 
regulon includes a bile acid efflux pump, CmeABC, which promotes resistance to bile 
acids133.  When bile is present in the environment, such as within a host intestine, CmeR 
becomes bound by bile acids which promoters a conformational change in the protein 
that releases the protein from DNA134.  This relieves CmeR repression and activates 
expression of the CmeR regulon, including the CmeABC bile acid efflux pump.  In this 
way C. jejuni senses an environmental que to transcriptionally respond to promote 
survival within a host. Studies looking at pathogen transcriptional changes during 
mammalian infection have revealed similarly important survival mechanisms – notably in 
human uropathogenic E. coli135– and have helped established examining transcriptional 
changes as a way to identify important adaptive mechanisms of survival during infection.   
The totality of gene transcription in a cell is called the transcriptome, which 
denotes the expression level of every gene in the genome136. Next-generation, high-
throughput nucleotide sequencing of total RNA from bacteria can be used to examine 
global transcriptional changes between bacteria grown in different environmental 
conditions or between different bacterial strains/isolates.  
To accomplish this, RNA is extracted from bacteria using guanidinium 
thiocyanate-phenol-chloroform extraction, or similar phenol-based extraction methods, 
which use chemical phase separation to separate RNA from genomic DNA and protein137.  
Addition of DNAse enzyme to extracted RNA can be used to eliminate contaminating 
genomic DNA form the extraction. As over 90% of RNA is unfluctuating ribosomal 
RNA (rRNA)138, removing rRNA makes it easier to characterize changes in non-
ribosomal RNA transcript levels139. So, DNA-free RNA can be incubated with ribosomal 
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RNA quenching probes, which bind to and physically sequester rRNA, so that only non-
rRNA remains in additional steps.   
After DNA and rRNA have been removed, a library of complementary DNA 
(cDNA) is made using a reverse transcriptase enzyme and polymerase chain reaction 
amplification.  This library can then be prepared for Next-generation sequencing using 
proprietary platforms, like Illumina140. This sequencing produces millions of reads of the 
cDNA which represents the original transcriptome of the bacterial sample population.  
These reads can then be bioinformatically mapped to the known, previously sequenced 
bacterial genome.  For a standard transcriptome analysis, each read is mapped to its 
homologous location in the genome, and the number of reads that map to annotated 
regions of the genome are counted, per gene and/or annotation. To compare if a particular 
gene had more mapped reads during growth one environmental condition (or perhaps 
expressed differently between bacterial isolates) and therefore showed differential 
expression between samples, the read mapping must be normalized141. A common 
method for this is to normalize the number of mapped reads to gene by the length of the 
gene and the total number of reads that were sequenced for that sample. A popular 
method for this normalization is called RPKM, for Reads mapped Per Kilobase of a gene 
per Million reads sequenced141. This helps remove bias in gene length (longer genes will 
have more reads map to them without necessarily having higher transcription levels) and 
normalizing for samples that have more or less total sequenced reads (more sequenced 
reads will result in more mapped reads despite transcription levels). Finally, RPKM 
values for every gene in the genome can then be compared between samples to determine 
which genes have expression changes between samples. A statistical test, such as 
Baggerly’s test142, should be applied to these data with a false-discovery rate (FDR) 
corrected p-value to identify statistically significant changes in gene expression.  
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Typically genes with a least a 3 fold change in expression with a FDR p-value of < 0.05 
are considered significantly changed between samples, although this arbitrary and may 
not be appropriate for all analyses. Notably, the biological relevance of a particular fold 
change is likely different per gene, and therefore significance cutoffs should be 
considered in the context of the scope of the work.   
Work in this dissertation used a similar method of RNA-sequencing to determine 
the C. jejuni and ETEC transcriptomes directly in human infection samples compared 
laboratory growths.  Additional complications arise when working with complex samples 
such as human feces.  First, additional rRNA removal steps must be included to remove 
eukaryotic rRNA. Second, partially digested food in feces is a potent inhibitor of DNAse 
during DNA removal.  To ameliorate this, a larger volume (~50ml vs 500ul) was used 
during guanidinium thiocyanate-phenol-chloroform extraction which produced greater 
physical separation of DNA from RNA during extraction to limit DNA contamination.   
Finally, only a small proportion of RNA extracted from infected feces is from the target 
pathogens, so billions of reads needed to be sequenced to get appropriate coverage of the 
genome. Strict mapping parameters - such as using 100% exact homology mapping to the 
reference genome - were used to eliminate non-specific transcripts from other bacteria 
influencing the results. These methods are described in more detail in the final chapter of 
this dissertation.   
1.4.2 Using Next-generation Genomic Sequencing to Reveal Mechanisms of 
Pathogen Success During Infection 
A variety of mechanisms can induce genomic mutations in bacteria, including 
errors made by DNA polymerases during replication and DNA damage and repair 
mechanisms.  Some genomic mutations are silent i.e. they do not alter the amino acid 
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sequence or expression of any gene or affect a regulatory element. These silent mutations 
have no observable influence of the fitness of the bacteria.  However, influential 
mutations, which do change protein coding sequences or regulatory elements can alter the 
fitness of the bacteria that harbor them131.  Influential mutations can either increase or 
decrease the fitness of bacteria52.  Bacteria with mutations that improve fitness will 
propagate more successfully than their neighbors and therefore eventually increase 
infrequency within the bacterial population.  Bacteria that harbor mutations that decrease 
fitness will allow neighboring bacteria to outcompete them, and therefore detrimental 
mutations will decrease in frequency in a population.  Some mutations are immediately 
lethal, for instance if they inactivate an essential gene required for replication143, and 
therefore they are immediately lethal to the bacteria and are therefore rarely detected 
within the populations. 
This concept of genetic variation leading to competing fitness over time is the 
basis of evolution and can be used to identify genetic elements that enable bacteria to be 
successful. In the past, various methods of identifying genomic loci responsible for 
bacterial phenotypes were used, including phage transduction and conjugation.  With the 
advent of high-throughput DNA/genomic sequencing entire bacterial genomes can be 
sequenced to identify all genetic differences between bacterial isolates and has been a 
boon for understanding bacterial diversity both between and within bacterial 
populations144.    
Importantly, genomic sequencing can be used to identify and track the spread of 
antibiotic resistance loci, precisely survey pathogen transmission between patients, and 
understanding the genetic selection pressures in complex environments6,7,145–147.  The host 
environment is remarkably complex - intestinal pathogens must survive in the context of 
a dense commensal microbiota, severe nutritional limitations, host digestive compounds, 
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ingested food, and an active host immune response.  Therefore, investigating genetic 
adaptations that are selected for in vivo can give unparalleled insight into the tools 
bacteria use to survive in vivo, as these adaptations could only arise while within this 
complex environment and would difficult to anticipate or replicate in the laboratory.   
This dissertation presents genomic sequencing of bacterial isolate populations 
before and after human infection.  Bacteria that naturally harbored beneficial genetic 
mutations outcompete their neighbors during infection and therefore increase in 
frequency in the infection population when compared to their frequency in the 
inoculum26.  Identifying these changes in frequency reveals the genetic adaptations that 
were selected during infection and therefore identifies the genes or “tools” the bacteria 
relied on to be successful in the human host.  
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Chapter 2: Campylobacter jejuni transcriptional and genetic adaptation 
during human infection 
2.1 INTRODUCTION 
Studying bacterial evolution during infection exposes how pathogens adapt and 
survive in the host. High-resolution whole genome sequencing enables accurate tracing of 
pathogen transmission between patients, identification of antibiotic resistance loci, and 
understanding of selective pressures in vivo6,145–149.  These developments have led to the 
identification of pathogen genetic variants that predict the success of treatments and 
guide therapy design.  Such studies reveal the extent of bacterial adaptability in vivo 
while regarding the genetic fitness compromises that would only arise in the complex 
host environment.  
Some bacteria adapt to new hosts and environments using a common population-
level adaptation method known as phase variability26.  Phase variation is driven by 
relatively high frequency genome mutations in homopolynucleotide tracts which result in 
a functionally “on” or “off” phase of affected gene(s)26. Subpopulations of on/off gene 
variants are intrinsically more fit for a new environment and therefore increase in 
frequency in a population as they outcompete less fit variants. This adaptive process 
genetically regulates virulence factors and is important for pathogen colonization and 
immune evasion51,52,150. 
 
1 Portions of this chapter have been previously published: Crofts, A., Poly, F., Ewing, C., 
Kuroiwa, J., Rimmer, J., Harro, C., Sack, D., Talaat, K., Porter, C., Gutierrez, R., 
DeNearing, B., Brubaker, J., Laird, R., Maue, A., Jaep, K., Alcala, A., Tribble, D., 
Riddle, M., Ramakrishnan, A., McCoy, A., Davies, B., Guerry, P. & Trent, S. 
Campylobacter jejuni transcriptional and genetic adaptation during human 
infection. Nature Microbiology 3, 494–502 (2018). Crofts conceived, designed, 
preformed and interpreted genetic and transcriptomic analyses and wrote the paper.  
Guerry, Trent, and Davies oversaw this study and edited the manuscript. All other 
coauthors contributed to primate studies.   
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To fully understand phase variable populations, whole genome sequencing can be used to 
identify the frequency of every “on” or “off” gene variant at the population level and then 
identify influential variants that are selected for during adaption to new host 
environments151,152. 
Campylobacter jejuni is a phase variable Gram-negative intestinal pathogen that 
causes bloody diarrhea, fever, and abdominal pain in humans. Notable secondary 
sequelae include Guillain-Barré syndrome, a potentially fatal paralytic autoimmune 
disorder. C. jejuni is a prevalent commensal bacterium in the intestinal tracts of chickens 
and other livestock, and consumption of contaminated animal products makes C. jejuni a 
leading cause of food-borne bacterial diarrhea worldwide. In low-resource areas, 
asymptomatic and sometimes persistent Campylobacter infections are common in 
children younger than 1 year old and correlate with stunted growth and therefore life-long 
physical and cognitive deficits2. In line with our understanding of in vivo pathogen 
evolution, small animal models of C. jejuni infection show host-passaged isolates are 
more fit in the host than the initial inoculum, and this genetic advantage remains even 
after multiple passages in vitro153. Here we use samples from a controlled human 
infection model to characterize the C. jejuni response to the human host. High-resolution 
genomic sequencing was used to track pathogen adaptation and phase variation in vivo, 
from inoculum through acute and persistent disease. In the challenge, a single liquid 
inoculum of C. jejuni strain CG8421 was used to simultaneously infect a group of human 
volunteers, making this study a highly-controlled pathogen adaptation experiment in 
humans. The challenge was designed to evaluate the prophylactic efficacy of rifaximin on 
C. jejuni infection in humans and is described elsewhere (ClinicalTrials.gov Identifier 
NCT02280044)61. Briefly, rifaximin treatment had no effect on the primary clinical 
outcome of campylobacteriosis. To be released from the trial, volunteers were treated 
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with azithromycin and ciprofloxacin and produced feces negative for C. jejuni. However, 
five volunteers experienced recrudescent154 infections. The clinical trial outcomes enabled 
us to compare pathogen gene variants that were selected for during both acute and 
recrudescent154 infections, as well as in volunteers who experienced severe disease or 
received prophylactic antibiotic treatment. We found variants of genes involved in host 
cell invasion, bile sensing, and flagella modification are selected for in recurrent human 
infections. To validate our approach, we performed a similar analysis in a symptomatic 
non-human primate infection model. Beyond defining genetic adaptation in primate 
hosts, we also used RNA-sequencing to determine the C. jejuni transcriptome directly in 
human infection samples.   
2.2 RESULTS 
2.2.1 Campylobacter Gene Expression in Human Infection Samples   
Responding to the host environment via transcriptional changes is essential for C. 
jejuni colonization and infection155,156. To identify the transcriptional adaptations that 
occur in a human host we determined the C. jejuni transcriptome directly in infected 
human feces of three volunteers. Compared to in vitro microaerobic growth on blood 
agar, 264 genes were differentially regulated in vivo by at least 3 fold (false-discovery 
rate adjusted p-value <0.05) (Fig. 2.1a, Sup. Table 1). A similar number of genes were 
differentially regulated compared to growth on Mueller-Hinton agar and in Mueller-
Hinton broth (Fig. 1a). No matter which comparison is made, a conserved group of 110 
genes were differentially regulated in vivo. These gene products include diverse 
characterized colonization factors, including Peb1A, PldA, CsrA, and the capsule 
polysaccharide transporter KpsM132,157–159.  These data also reveal only between 10 and 15 
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percent of annotated open reading frames show significant differential regulation in 
infected human feces compared to growth in standard laboratory conditions.  
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Figure 2.1: The C. jejuni Transcriptome in Human Infection and Chick Commensalism. 
a, Differentially regulated genes in vivo. A Venn diagram showing the number of 
differentially regulated C. jejuni CG8421 genes (fold change >|3|, FDR p-value <0.05) in 
the infected feces of three volunteers compared to laboratory control growths which each 
represent three biological replicates. b, Human infection versus chicken commensalism 
transcriptomes.  A Venn diagram showing the number of differentially regulated (fold 
change >|3|, FDR p-value <0.05) gene homologs in vivo between C. jejuni CG8421 
infected human feces (3 samples) and a previously published RNA-seq transcriptome of 
C. jejuni 81-176 in the chicken cecum, which represents 3 pools of 5 infected chick ceca 
each. Both data sets use mid-log phase growth in Mueller-Hinton broth biological 
triplicates as the in vitro lab comparison. c, Conserved differential gene regulation across 
hosts, lifestyles, and strains.  The 39 differentially regulated homologs from Fig. 1b 
conserved between human infection and chicken commensalism with transcriptional fold 
changes noted. d, The top most upregulated and downregulated CG8421 genes in human 












































Role                   chuA Iron Acquistion chuA Heme receptor CJJ81176_1566 (sapD) Antimicrobial Peptide Resistance 
8.75171                   chuD Iron Acquistion
7.908101                   chuZ Iron Acquistion
3.456996                 exbB2 Iron Acquistion
0.692233 CJJ81176_1649 Iron Acquistion
1.363168                   ceuB Iron Acquistion
16.39697
0.633589                    pstS Inorganic Phosphate Uptake
0.584658                    pstB Inorganic Phosphate Uptake
2.841918
3.228087                    katA H2O2 Defense
3.852189                   ahpC H2O2 Defense
0.692233                     cjtK H2O2 Defense
1.363168 CJJ81176_1184 H2O2 Defense
1.281123 CJJ81176_1388 H2O2 Defense
1.678777
1.11819                   dsbB Disulfide Bond Formation
1.302746                     dba Disulfide Bond Formation
1.206782
0.846297 CJJ81176_1386 Fumarate Reduction
                   fdhU Formate Utilization
1.057359                    fdhT Formate Utilization
8.003814                  dmsB DMSO Utilization
6.930524
                  hspR Stress Response Regulation
320.8162                    hrcA Stress Response Regulator
12.6127                    clpB Chaperone
0.584658                   dnaK Chaperone
3.125907
3.125907                   metB Amino Acid Biosynthesis (Methionine) 
87.98037                   metE Amino Acid Biosynthesis (Methionine) 
0.669446                   metF Amino Acid Biosynthesis (Methionine) 
0.947586                    glnA Amino Acid Biosynthesis (Glutamine)
CJJ81176_0683 Peptide Transport
4.469776
4.720839                      pal Immunogenic Outer Membrane Protein
1.161852                     flgP Motility
1.949229 CJJ81176_0444 Hypothetical
CJJ81176_0847 Hypothetical 




















































Role                   chuA Iron Acquistion                   chuA Hem  receptor CJJ81176_1566 (sapD) Antimicrobial Peptide Resistance 
                  chuD Hemin ABC transporter
                    cfrA Enterobactin transporter
                exbD1 TonB system transport protein 
CJJ81176_1386 Conserved hypothetical protein
                   katA Catalase
CJJ81176_1388 Ankyrin repeat protein
CJJ81176_1246 Hypothetical protein
                  HypF Hydrogenase
CJJ81176_1653 ABC transporter, permease 
CJJ81176_0870 Conserved hypothetical protein
CJJ81176_0289 Methyl-accepting chemotaxis protein
                   glnA Glutamine synthetase
CJJ81176_0280 Conserved hypothetical protein
                    gltD Glutamate synthase
CJJ81176_1493 Conserved hypothetical protein
CJJ81176_0316 Glycerol-3-phosphate transporter
                acpP3 Acyl carrier protein, putative
CJJ81176_0387 Hypothetical protein


















Although primates can experience disease symptoms during infection, C. jejuni 
has a commensal lifestyle in the natural bird host.  To relate transcriptional adaptations 
that occur during infection and commensalism, we compared our data to a previously 
published RNA-sequencing data set of C. jejuni strain 81-176 in the chick cecum (Fig 
1.1b, Sup. Table 2)160.  We identified a core set of 39 conserved genes that are 
differentially regulated in vivo across hosts, colonization lifestyles, and strains.  These 
gene products share strikingly similar roles, including iron acquisition, inorganic 
phosphate uptake, and protection from peroxide stress (Fig. 2.1c). Epithelial cell 
production of hydrogen peroxide plays an important role in mucosal immunity against C. 
jejuni. Hydrogen peroxide-mediated inactivation of the C. jejuni outer membrane tyrosine 
kinase Cjtk leads to a decrease in capsule production and therefore decreased virulence161.  
Here we see the importance and conserved nature of this response as cjtK along with two 
major hydrogen peroxide scavengers, katA and ahpC, are upregulated during both 
chicken commensalism and human infection. Finally, 7 of these 39 genes showed 
discrepant expression patterns. Notably, the fdhTU operon, which is important for 
formate dehydrogenase activity162, is oppositely expressed between the human and chick 
data.   
The most upregulated genes in human infection samples represent two distinct 
iron acquisition pathways. The chuA and chuD hemin uptake genes, and cfrA, a ferric-
enterobactin uptake gene, are all upregulated >100 fold in vivo (Fig. 2.1d). chuA is not 
required for chicken colonization163 and is modestly upregulated in the chick cecum (<10 
fold increase in vivo), although it is highly upregulated in human infection samples 
(>1000 fold increase in vivo). There are 161 genes that are differentially regulated 
specifically in our human samples and not in the chick cecum (Fig. 2.1b) and includes the 
highly upregulated cfrA. C. jejuni does not produce siderophores, but CfrA enables 
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import of a wide array of siderophores made by other organisms and, unlike chuA, is 
required for chicken colonization50.  This suggests microbiome derived siderophores and 
cfrA play an important role in C. jejuni infection of humans.   Interestingly, components 
of the Sap antimicrobial peptide resistance efflux pump, which is required for chicken 
colonization164, are also uniquely upregulated in human infection (Fig. 2.1e). 
2.2.2 Genome Variant Selection During Human Infection 
To identify genetic variants that are selected for during human infection we 
examined the genome of C. jejuni before and during acute and persistent human 
infections. We sequenced the genomes of 49 C. jejuni CG8421 infection isolate 
populations from 14 volunteers during acute and recrudescent infections and compared 
them to the inoculum genome (Fig. 2.2a, Fig. 3).   
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Figure 2.2 C. jejuni Genomic Variants are Consistently Selected for During Human 
Infections 
a, Infection populations sequenced.  Whole genome sequencing was performed on 49 
infection isolate populations, taken from 14 volunteers across 6 days of primary infection.  
5 volunteers relapsed after the clinical trial, and those infection isolate populations were 
also sequenced.  Some volunteers experienced severe disease on the noted days (red) and 
therefore received early antibiotic intervention. Some volunteers received exploratory 
prophylactic treatment with the antibiotic Rifaximin as noted.  Sequencing details are 
noted in Fig. 2.3.  b, Genomic variants detected per volunteer isolate population, noted by 
the genes the variants affect.  The number of genomic variants detected per infection 
population is noted on the y-axis, and the x-axis denotes the day and volunteer the sample 
was taken from, with R denoting a relapse sample.  The corresponding genes are listed by 
their gene name or annotation when considering homologs across CG8421, 11168, and 
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Illustration 2.1 Schematic of Genome Variant Analysis 
The genomes of the C. jejuni CG8421 inoculum and infection isolate population genomes 
were compared to the published reference genome. Genome variants that occurred in at 
least 1 percent of any sample population are listed in Sup Table 1C.  However, to identify 
influential variants we used a 25 percent frequency cutoff as described in the methods 
and paper text, and those variants are listed in Sup. Table 4. The variant calls between the 
inoculum genome and the infection isolate populations where then compared, and variant 
calls that differed between the inoculum and isolate populations are considered genomic 
variants selected for in vivo. Using the location of each variant in the annotated genome 
we determined the genes (or gene promoters) affected by these variants, and then used 
Fisher’s Exact Test with FDR-corrected p-values to determine if particular genes were 
more likely to genetically vary in in vivo between volunteer isolate groups. 
 
These infection isolate populations represent bacterial colonies harvested directly 
from primary isolation plates and are pooled together per sample with no further 
outgrowth, and is consistent with previous work that validated C. jeuni isolate sequencing 
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to study genetic variation in vivo26. We achieved exceptional coverage of the infection 
population genomes across all samples, with an average genome sequencing coverage 
>1000x and 97 percent of genes had at least 25x coverage at every nucleotide position 
(Fig. 2.3).  
Figure 2.3 Infectious Isolate Populations Genome Sequencing Coverage 
a, Sequencing depth across all 49 infection isolate populations. The average fold 
coverage across samples was 1192x (orange line). b, Coverage of open reading frames 
across samples. On average (orange line) 98 percent of annotated genes had at least 25 
fold coverage at every base across samples. Grey bar represents the number of genes 
where at least one nucleotide had <25x coverage.  Blue bar represents the number of 
genes where every nucleotide in the gene had >50% of mean coverage (1192x mean 
coverage across all samples). 
Due to the complexity of phase variable populations, different subjective methods 
have been used to determine noteworthy changes in phase variant frequencies over 
time26,54,151. We first called any variant that occurred in at least 1 percent of any sample 
population, which resulted in over 600 variants identified across all samples.  To focus on 
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large portion of the population, we called variants in a sample if they occurred in at least 
25 percent of the population.  This enriched for variants that had, on average, a large 
statistically significant fold change in frequency between the inoculum and an infection 
isolate populations (~12 fold) while also representing a majority of the infection 
population sample (~60 percent) (Fig. 2.4).  
Figure 2.4 Average 
Frequency of 




called if they 
occurred in at least 
1 percent of a 
sample population 
(49 isolate samples 
and 1 inoculum), 
resulting in over 
600 variants 
detected across all 
samples, and that 
data is found in 
Sup. Table 3.  To 
focus on variants that had both a large change in frequency during infection and 
represented a large portion of the population, we used a 25 percent variant calling cutoff.  
This raised cutoff enriched for variants that had, on average, a large fold change in 
frequency between the inoculum and an infection isolate populations (~12 fold) while 
also representing a majority of the infection population (~60%). Detailed information 
about each variant call, per sample, is provided in Sup .Table 5 and is represented here by 
a dot plot. An unpaired two-tailed T-test was used to confirm a significant difference in 
the mean frequency between the pre (inoculum) and post infection (Isolate Population) 
variant frequency calls. Bars represent the mean variant frequency in the sample(s) and 
standard error of the mean.    
This enrichment analysis resulted in 48 unique genomic variants with major 
changes in frequency in at least one sample, including small nucleotide polymorphisms 
 


























(SNPs), phase variations (PV), and multinucleotide variants (MNV). 47 of the variants 
clearly affected 30 annotated coding sequences and/or promoters and are noted per isolate 
population in Figure 1.2b. Slip-strand mutations in poly G/C nucleotide tracts are the 
dominant phase variable mechanisms in C. jejuni26, and 19 of 28 tracts in the CG8421 
genome varied in at least one infection isolate population (Fig. 2.5).  The inoculum 
population had 12 genetic variants that differed from the reference genome, 4 of which 
remained intact in all infection isolate populations.  
Figure 2.5 Poly G/C Tract 
Locations and Variations in 
Vivo 
The location of all 28 poly 
G/C tracts in the CG8421 
genome are presented by 
their relationship to 
annotated open reading 
frames in a stacked bar 
graph.  The number of tracts 
at each location type that 
varied in at least one sample 




Three genetic variants were selected for in all 49 infection isolate populations 
(Figure 1.2b).  One of these completely conserved variants is a PV that occurs in the in 
last 10 percent of the fedA gene open reading frame and in the -10 promoter region of an 
overlapping downstream gene of unknown function. fedA is putative hemerythrin that 
contributes to C. jejuni colonization in chicks and is coregulated with flagellar gene 
expression36.  A second completely conserved variant is a SNP in the house keeping gene 
 























































adenine phosphoribosyltransferase (apt) which salvages adenine to make adenosine 
monophosphate.  The inoculum population contained an apt SNP that is selected for 
during osmotic stress54, however the wild type apt sequence was selected for in vivo.  The 
final completely conserved variant is a 9 nucleotide in-frame deletion in the CG8421 
homolog of the DNA response regulator CJJ81176_1483 that was selected against in 
vivo. Selection for the wild type version CJJ81176_1483 in vivo was confirmed by 
structural genomic variant analysis. CJJ81176_1483 is part of a newly identified two-
component system that regulates a gluconate dehydrogenase complex important for chick 
colonization165. These data represent 3 distinct genetic variations (PV, SNP, and MNV) in 
genes with diverse roles (chicken colonization, osmotic stress/house keeping, two-
component system) and demonstrate the genetic adaptability of C. jejuni in vivo. 
2.2.3 Gene Variants Associated with Treatment or Human Disease State 
Rifaximin prophylactic treatment did not impact the rate of campylobacteriosis 
during the clinical trial.  Nevertheless, we hypothesized the antibiotic treatment 
environment in the host may have selected for unique genomic variants in these 
volunteers. However, we found no variants were more likely to be called in these 
volunteers when compared to control volunteers using Fisher’s Exact Test. We concluded 
rifaximin did not exert a noticeable pressure on C. jejuni in vivo. We also hypothesized 
some variants may be more virulent, and therefore would be more likely to be found in 
volunteers who experienced severe disease symptoms. However, a Fisher Exact Test 
showed no variants were associated with isolates from volunteers experiencing severe 
disease compared to typical symptomatic disease isolate populations. This indicates host 
factors, more so than genetic drift of more virulent genotypes, may influence the severity 
of disease symptoms. 
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Despite being treated with azithromycin and ciprofloxacin and repeatedly 
producing feces negative for C. jejuni isolates at the end of the trial, 5 volunteers returned 
to the clinic with at least one bout of recrudescent infection (Fig. 2.2a). This rate of 
recrudescence is higher than previous trials likely due to enhanced culture techniques, 
such as not refrigerating stool before culturing, that were employed specifically for 
increased vigilance of recrudescence61.  Recrudescent infection isolates were confirmed 
to be the inoculum strain and, in all cases, were sensitive to azithromycin and 
ciprofloxacin. Remarkably, relapse infection isolate populations had twice as many 
genomic variants as primary infection isolates (Fig. 2.6a). We hypothesized the increased 
variant count would correlate with increased time in vivo. To test this, we compared the 
number of variants called per sample on every day of infection. Interestingly, there was 
not an increase in the number of variants called over time during the primary infection 
(Fig. 2.6b) and a Fisher exact test showed no particular variants are associated with early 
or late primary infection periods. These data suggest there is an immediate and consistent 
selection pressure during primary infection, and that either a secondary selection event or 
additional time within the host results in increased genetic variation of relapse isolates.  
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Figure 2.6 Particular Genome Variants are Associated with C. jejuni Recrudescent 
Infection Isolate Populations 
Caption for Figure 2.6 begins on following page.  
 





























































































































































































































































































































































































Caption for Figure 2.6: 
Primary infection isolates (days 0-6) represent 43 isolate samples while relapse infection 
isolate populations represent 6 samples. a, Bulk genome variation between primary and 
relapse infection isolates.  On average, relapse infection isolates have twice as many 
genomic mutations compared to primary infection isolates (Unpaired two tailed T-test 
with bars representing the mean and standard error of the mean). b, Variant accumulation 
over time.  Variants are selected for immediately in human infections (day 0 is the day of 
inoculation); however, they do not increase over time during the primary infection (One-
way ANOVA, Tukey’s multiple comparison test). c, Genome variants that are associated 
with relapse infection.  After the genome variants were determined for all samples (Fig 
2b), a Fisher’s Exact test was used to determine if variation in particular genes is 
associated with relapse infection isolate populations. Variation of 10 genes was 
statistically associated with relapse infection populations and is noted with a False-
Discovery Rate adjusted (FDR) one-sided p-value of < 0.05. The y-axis represents the 
percent of samples that had a variant in the gene noted on the x-axis. More detailed 
information is noted in Sup. Table 4.  
 
There are a considerable number of genetic variants that are associated with 
relapse infection isolates as determined by Fisher Exact Test (false-discovery rate 
corrected p-value <0.05) (Fig. 2.6c, Sup. Table 10). Of the 10 gene variants associated 
with relapse infection only 3 are characterized, named genes.   The most striking is a 
phase variation in cipA (cell invasion protein A), which turned the gene “on” in every 
relapse infection isolate population, but does not appear to be important for establishing a 
primary infection.  cipA was identified in three independent studies to contribute to C. 
jejuni invasion of host cells in vitro34,166; however, this gene has not been shown to play a 
role in vivo until this work in a human challenge model. Mechanisms of C. jejuni cellular 
invasion are not well defined and no biochemical functions of CipA have been previously 
identified. Although, BLAST search revealed cipA harbors a domain of unknown 
function (DUF2972) that is also found genes annotated as glycosyl transferases. To 
determine the role of CipA during human infection we therefore considered possible 
glycosylation targets.  We find the “on” variant of cipA that was selected for in vivo 
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results in modification of the flagella (Figure 1.8a). This suggests cipA likely contributes 
to cellular invasion and persistence in humans via flagella modification. 
 
Figure 2.7 Genetic Variation in Flagella Modification Genes is Strongly Associated with 
the Human Disease State 
Caption for Figure 2.7 begins on the following page.   
  





Caption for Figure 2.7:  
a, A functional cipA gene results in modification of the flagella as shown by an 
isoelectric focusing gel (pH 3-5) of purified flagellins from C. jejuni strain 81-176. The 
cipA gene was phase varied “off” in the human inoculum, but was selected to be turned 
“on” in every human relapse infection isolate population. Therefore, a functional cipA 
gene is strongly associated with relapsing human infections. We therefore aimed to 
identify the biochemical role of cipA in Campylobacter. cipA contains a domain of 
unknown function found in putative glycosyl transferase genes as predicted by BLAST 
search. We therefore sought to identify possible targets of cipA activity in 
Campylobacter. We investigated potential flagella modification by preforming an 
isoelectric focusing gel mobility shift assay on purified flagella from cipA “on” and “off” 
genetic backgrounds. Flagellin modification activity changes the electrical charge of the 
flagellin and therefore results in a mobility shift in the delicate isoelectric focusing gel. 
Therefore, in lieu of standard ladders, purified flagella from characterized intact and 
mutant flagella modification strains are used as simultaneous markers and reference 
controls to interpret modification-induced shifts on IEF gels. Genetic manipulation 
cannot be performed in strain CG8421 so strain 81-176 was used for these analyses. 
Lanes contain flagellin from:  pseA, a mutant lacking the acetamidino form of 
pseudaminic acid, serving as a control demonstrating a more negatively charged 
modification state compared to wildtype; WT, wildtype 81-176 flagellin in which pseA is 
intact, however cipA is “off” similar to the human inoculum; cipAR, a mutant in which 
the phase variable homopolymeric G tract in cipA was repaired to produce a full-length 
cipA open reading frame in an otherwise WT background. Indeed, a mobility shift of 
flagella from the cipA “on” repaired strain indicates a more negative charge and therefore 
cipA contributes to flagellin modification. Samples were repeated in multiple lanes for 
clarity of the phenotype and this gel is representative of at least 5 mobility shift 
experiments.   b, Contingency table of variable genes and their association with either 
primary or relapse infections (disease state). A Fisher’s exact test shows variation in 
flagella modification genes (including O-link glycosylation locus genes as described in 
Sup. Table 4) as a group is strongly associated with either primary or relapse infection 
isolate populations (one-sided p-value).  The 8 variable genes related to flagellin 
glycosylation1 are Cj11168 homologs Cj0617/618, Cj1295, Cj1306c, Cj1325, Cj1342, 
Cj1333, Cj1321 (CJ8421_RS06560), and cipA as identified in Sup. Figure 6a.  c, 
Isoelectric focusing gel of flagellins from C. jejuni strain 81-176 and 81-176 mutants. 
Cj0617 and Cj0618 are phase variable genes that can be translated as a unified open 
reading frame (Cj0617/618). Although Cj0617 is the representative gene of the 617 
family of O-linked glycosylation genes2, and Cj0618 contributes to motility3, Cj0617 and 
Cj0618 are the only genes included in Sup. Fig. 6b, besides cipA, that are not located in 
the O-linked glycosylation locus and there are no reports showing the affect of 
Cj0617/618 on flagellin modification to our knowledge.  
 
Caption for Figure 2.7 continues on the following page. 
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Figure 2.7 caption continued…We therefore sought to verify that Cj0617/618 contributes 
to flagella modification by preforming an isoelectric focusing gel mobility shift assay on 
purified flagella. Flagellin modification activity changes the electrical charge of the 
flagellin and therefore results in a mobility shift in the isoelectric focusing gel. Therefore, 
in lieu of standard ladders, purified flagella from characterized intact and mutant flagella 
modification strains are used as simultaneous markers and reference controls to interpret 
modification-induced shifts on IEF gels.  Genetic manipulation cannot be performed in 
strain CG8421 so strain 81-176 was used for these analyses. Lanes contain flagellin from:  
pseA, a mutant lacking the acetamidino form of pseudaminic acid, serving as a control 
demonstrating a more negatively charged modification state compared to wildtype; WT, 
wildtype 81-176 flagellin in which pseA is intact, however Cj0617/618 is not translated 
as a continuous open reading frame; Cj0617/618R, a mutant in which the phase variable 
homopolymeric G tract was repaired to produce a continuous open reading frame of 
genes Cj0617 and Cj0618 in an otherwise WT background. Indeed, a mobility shift of 
flagella from the Cj0617/618 repaired strain indicates a more negative charge and 
therefore Cj0617/618 contributes to a flagellin modification phenotype. This mobility 
shift is representative of at least 5 mobility shift experiments. Cj0617/618 likely affects 
pseudaminic acid modifications on flagellin as strain 81-176 lacks the alternative 
legionaminic acid pathway. 
Another notable gene associated with relapse infection is cmeR, a pleotropic bile-
sensing transcriptional regulator that is required for chicken colonization130. CmeR 
functions as a dimer to bind DNA and repress gene expression until C. jejuni is exposed 
to bile in the intestinal environment134. CmeR repression is relieved upon bile acid 
binding, which induces expression of the CmeR regulon including the multi-drug efflux 
pump cmeABC167. Two unique SNPs that each resulted in truncation of the cmeR open 
reading frame were selected for independently in relapse infection isolates and are in 
non-phase variable loci. Similar truncations have been shown to prevent dimerization of 
CmeR and therefore prevent CmeR repression regardless of environmental bile 
concentrations168. cmeR was intact in every primary infection isolate, and likewise, 
functional CmeR protein is important for colonization of chickens. However, the 
independent and functionally conserved relapse variants suggest a cmeR “off” mutation 
can be advantageous in persisting human infections.  This may be due to a resulting 
constitutive expression of the CmeABC efflux pump that increases resistance to bile 
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acids in the host133, although losing the ability to sense bile is an unexpected in vivo 
phenotype for an intestinal pathogen.  
pseD is the final named gene variant that is associated with relapse infection.  
PseD attaches pseudaminic acid to flagellin which contributes to virulence-associated 
autoagglutination of the bacteria169. pseD was considered “on” in every primary infection 
sample but turned “off” in a one third of relapse infection samples.  The remaining 7 
relapse associated gene variants included hypothetical genes, a disrupted aminopeptidase 
gene, a methyltransferase gene, and two additional O-linked glycosylation locus genes.  
Interestingly, an annotated methyltransferase and multiple O-linked glycosylation locus 
genes were identified to be under positive selection in a study of Burkholderia infection 
of cystic fibrosis patients6, although these genes share low sequence homology with 
genes in CG84216.   
Figure 2.8 Genome Variant 
Associated Only With 
Primary Infection Isolate 
Populations 
A phase variant in the 
promoter region of the 
uncharacterized putative 
transferase gene 
CJ8421_RS06560, present in 
the inoculum, was 
resoundingly selected against 
during primary infection of 
humans.  The percentage of 
isolates shown denotes the frequency that the wildtype (reference sequence) variant was 
called in those samples.  Fisher’s exact test identified this variant as statistically 
significantly associated with primary infection isolates (43 samples) compared to relapse 
infection isolates (6 samples) with a false-discovery rate (FDR) correct p-value.     
 
 























FDR p-value < 0.004
Phase	Variation	in	the	Pr mot r	Region	of	CJ8421_RS06560	
 51 
One variant is statistically significantly associated with primary infection isolates 
and not relapse infection isolates (Fig. 2.8).  This is a phase variant in the promoter 
region of an uncharacterized putative transferase gene, CJ8421_RS06560 (homolog of 
Cj1321 in strain NCTC_11168), located in the flagellin glycosylation locus170 and was 
strongly selected against in primary infection isolates, but not in relapse infection 
isolates. In total, 7 of the 8 flagella modification genes identified in our analysis are 
associated with either primary or relapse infection isolates, indicating the significance 
and variability of flagellar modification during human infections (Fig. 2.7b). Finally, 
Figure 2.9a depicts a SNP-tree analysis to visually represent the differences in genomic 
variations amongst primary and relapse infection isolates.  The closer two samples are on 
the tree, the more similar their genomic variant profiles are to one another. Primary 
infection isolates from the same volunteer are more similar to each other than they are to 
the isolates of other volunteers.  However, the relapse infection isolates from different 
volunteers are more similar to each other than they are to the founding primary infection 
isolates from the same volunteer. Overall, the relapse-associated variants demonstrate the 
profound genetic differences that occur in persisting bacteria.  
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Figure 2.9 Validating C. jejuni Genomic Variant Selection in non-Human Primates 
a, A SNP tree representing how similar human infection isolate populations are to one 
another.  Each wedge represents one sequenced isolate population and the closer two 
samples are to each other the more similar their genomic variations. Volunteer 
identification numbers per sample are noted on the outside of the ring, and the day of 
infection and the number of SNPs detected are denoted by the inner rings.  Note that 
primary infection isolates from the same volunteer are more similar to each other than 
they are to isolates from other volunteers. However, relapse infection isolates (bright 
orange) are more similar to each other despite the volunteer they come from.  b, 
Conserved gene variant selection across primates.  A second, different C. jejuni CG8421 
inoculum was used to infect owl monkeys, and the genomes of 12 diarrheal primary 
infection isolate populations from 5 monkeys were sequenced (Table 1.1). The Venn 
diagram shows the C. jejuni genome variants selected for in owl monkey infection 
closely resemble those of human infection. This supports the human data and suggests 
non-human primates harbor a similar fitness selection environment found in humans.  
The smaller sample size and no relapse infections contributed to fewer total variants 
detected in the monkeys.   
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2.2.4 Genome Variant Selection in Aotus Primates 
The variants selected for during human infection replicated strongly across 
volunteer isolate populations. This powerfully suggests a conserved selective pressure 
and adaptive response in vivo. However, over 30 coding sequences were implicated in 
adaptation, and understanding the fitness contribution of variant combinations within the 
population is challenging. To validate our data and respect the complexity of population-
level adaptation, we performed a similar analysis in a symptomatic non-human primate 
infection model.  We hypothesized adaptations similar to those in human infection would 
be selected for in a New World monkey, Aotus nancymaae. An independently prepared 
CG8421 liquid inoculum was used to infect Aotus nancymaae and we compared this 
inoculum genome to 12 diarrheal isolate populations taken over 8 days of infection from 







Table 2.1: Non-human primate infection and samples used. 
Despite differences between the human and Aotus inoculums, we found the 
genetic adaptations selected for in Aotus closely resemble those in humans (Fig. 2.9b). 
The 3 completely conserved variants that were selected for in human infection were 
already present as a majority in the Aotus inoculum, and congruently, were maintained 
during infection. Two genes were uniquely varied in Aotus infection, including a SNV in 
the promoter region of CJJ81176_1215, a gene encoding an uncharacterized, putative 
NLPA-family lipoprotein. Interestingly, the second variant is a E70K amino acid 
substitution in chuA, which is also the most upregulated gene during human infection. 
Therefore, chuA can undergo both transcriptional and genetic adaptations during primate 
infection. Few of the genetically variable genes were also differentially regulated in vivo, 
yet this is consistent with analyses done in vitro171 and in vivo172 that show genes that 



















2.3 DISCUSSION OF C. JEJUNI IN VIVO ADAPTATION 
Understanding the bacterial pathogen response to the human host revealed genetic 
mechanisms of success during both establishment of infection and persistent human 
colonization.  Notably, we determined the cipA gene had the strongest association with 
recrudescent, persistent infections, and we went on to identify its role in C. jejuni 
flagellar modification. 9 other variable genes are part of the conserved relapse infection 
genotype. We suspect this genetic background may enable bacteria to reside in a 
protected niche within the host during primary infection where they withstand being shed 
from the host, resist antibiotic treatment and the host immune response, and result in 
recrudescent infection. This genotype would then be the dominant recrudescent 
population, and a similar pattern was seen in this study.  Future therapy design should 
consider the “on/off” status of a therapeutic target throughout primary and recrudescent 
infections, as well as appreciate target expression alterations due genetic variation of 
promoter regions or transcription factors such as CmeR. 
Tracking pathogen evolution in vitro requires studying multiple cultures grown in 
parallel, and variants that arise consistently across replicates are considered adaptive. 
Studying pathogen evolution in vivo can reveal important virulence determinants, 
although it is difficult to study well-controlled human infections in parallel. Here we used 
a C. jejuni clinical trial to examine bacterial adaptation during human infection and found 
many genomic variants are well conserved across infected volunteers. We also found 
human infection exemplifies rapid bacterial adaptation, as variants are selected for in vivo 
on the day of inoculation. This study characterizes pathogen genetic and transcriptional 
adaptations across hosts and lifestyles, and similar collaborative approaches in future 
clinical studies may increase the possibilities for therapeutic design.    
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Chapter 3: Enterotoxigenic E. coli Virulence Gene Regulation in 
Human Infections  
3.1 INTRODUCTION 
Enterotoxigenic Escherichia coli (ETEC) is a global gram-negative diarrheal 
pathogen of the small intestine that infects up to 200 million people worldwide each 
year3.  ETEC infections result in hundreds of thousands of deaths annually and rely on a 
trio of classical ETEC virulence factors to cause disease3,80,4. The prototypical ETEC 
strain H10407 harbors heat-labile and heat-stable enterotoxins along with the 
colonization factor antigen (CFA) adhesin85. The production of CFA is controlled by the 
transcriptional regulator CfaD, which activates the expression of the cfaABCE operon on 
virulence plasmid p948173. The outer membrane usher protein CfaC and periplasmic 
chaperon CfaA assemble the extracellular CfaB pillus with the CfaE adhesive tip87,95. 
Robust CFA adhesin production occurs in CFA media, a namesake standard ETEC 
complex growth media. 
     Alongside the CFA adhesin, H10407 also harbors the heat labile toxin and two 
homologs of the heat stable toxin denoted as sta1 and sta280,110,174.  The enzymatic activity 
of these enterotoxins results in water efflux from host intestinal cells which produces 
profuse diarrhea175,176. sta1 and sta2 are found on plasmids p666 and p948, respectively. 
Despite their conserved functional role, sta1 and sta2 have different promoters and their 
expression can be inversely regulated129.  Recent work has shown the cyclic AMP 
receptor protein (CRP), in response to changes in extracellular glucose concentrations, 
can oppositely regulate sta1 and sta2 promoter::lacZ fusion reporter constructs in E. coli 
K-12129. The significance of differential regulation between two heat stable toxin 
promoters remains unclear, although it demonstrates how a single environmental factor 
can have a complex effect on virulence factor expression in ETEC. Heat labile toxin is a 
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heterohexameric, A-B subunit enterotoxin encoded by the eltAB operon on virulence 
plasmid p666177. It is functionally and structurally similar to the diarrhea inducing cholera 
toxin produced by Vibrio cholerae177,178.    
     Although ETEC H10407 contains all of these classical virulence factors, only 
one enterotoxin is required for symptomatic disease86. ETEC also contains a large group 
of non-classical179 virulence factors that have been shown to contribute either directly or 
indirectly to virulence-related phenotypes in E. coli.  Notably, genes etpABC180 and 
tibAB181 were originally described in ETEC, and have been shown to enable host cell 
adhesion in vivo and host cell adhesion/invasion in vitro, respectively.   
     Decades of research on classical virulence factor gene regulation in ETEC has 
demonstrated how over 20 environmental conditions influence expression of individual 
virulence genes, including pH, bile, bicarbonate, osmolarity, and glucose129,173,182.  
Understanding how ETEC responds to these signals in the mammalian intestinal tract for 
effective colonization and transmission is challenging, particularly considering just one 
of these factors can alter expression of virulence factors in opposing ways. For example, 
it was recently shown glucose can oppositely regulate heat stable and heat labile toxin 
promoter::lacZ fusions129, and there are scarce reports of all virulence factors regulated in 
a similar manner simultaneously.  
     Successful intestinal colonization requires appropriate bacterial transcriptional 
adaptation to the host environment. We therefore examined the ETEC transcriptome in 
human infection samples to understand how ETEC responds to the host in vivo.  The 
host-specific response has important implications for therapy design as it can reveal that 
high priority drug and vaccine targets may have unexpected expression patterns in vivo9.  
Here we used samples from a controlled human infection model to examine the global 
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transcriptome of ETEC H10407 directly in human infection samples (ClinicalTrials.gov 
Identifier NCT01922856).   
     The human challenge was developed to test the efficacy of a vaccine 
immunization against CfaE and heat labile toxin to prevent diarrheal episodes in humans 
and will be detailed elsewhere. We performed RNA-sequencing directly on the stool 
samples of 5 infected volunteers who were not given vaccine treatment.  Many studies 
have investigated the expression of individual ETEC genes in infected stool samples; 
however, variation between wild type isolates can make interpretation of these data 
challenging.  In this study, each volunteer was infected simultaneously from the same 
H10407 inoculum.  This allowed us to study biological replicates of human infection 
without confounding differences between strains or inoculums, and further, we performed 
a global analysis of ETEC gene expression directly in the infected samples using next-
generation high throughput RNA-sequencing.   
     We were surprised to find the heat-labile toxin genes and CFA adhesin 
expression were down regulated in infected stool samples compared to laboratory growth 
in CFA media. After considering the stool samples represented the anaerobic large 
intestinal environment, and that little work has been done to characterize ETEC in low-
oxygen conditions, we examined the ETEC transcriptome during growth in microaerobic 
and anaerobic atmospheres. Besides the anaerobic large intestinal environment, anaerobic 
conditions in the proximal small intestine are fortified by bacterial overgrowth183 and the 
distal small intestinal lumen naturally has near zero levels of oxygen184. Remarkably, we 
discovered anaerobic in vitro growth fully replicated the virulence gene expression 
pattern seen in the stool samples, indicating environmental oxygen played an important 
role in understanding virulence factor expression in vivo.  Anaerobic growth in vitro 
results in a significant decrease in expression of cfaD, the cfa operon, and the eltAB 
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operon, and an increase in sta2 expression when compared to aerobic growth. We went 
on to determine the effect of oxygen on virulence gene expression is dependent on the 
oxygen-sensitive transcriptional regulator FNR185,186 (Fumarate Nitrate reduction 
Regulator).  Deletion of fnr in H10407 resulted in a significant increase in expression of 
all classical virulence factor genes, including both sta1 and sta2, indicating FNR activity 
results in a global repression of virulence gene expression in ETEC.   
     We also found that H10407 produces significantly more biofilm when grown 
anaerobically compared to aerobic growth, and that a Δfnr H10407 strain produces 
significantly more biofilms than WT under anaerobic conditions. In afflicted areas, ETEC 
biofilm formation on abiotic surfaces is correlated with seasonal epidemics84, which 
suggests FNR-dependent oxygen-sensing may contribute to human ETEC infection both 
inside and outside of the host.       
     Overall, by examining the transcriptome of ETEC in infection samples from a 
controlled human infection model, this study identified an environmental factor and 
corresponding transcriptional regulator that influences global virulence and biofilm 
regulation.  This work suggests the low oxygen environment of the intestinal lumen likely 
represses ETEC virulence gene expression in vivo - particularly when bacterial 
overgrowth fortifies anaerobic conditions in the proximal small intestine183,187, in the 
distal small intestine where luminal oxygen levels are near zero184, and in the anaerobic 
large intestine during transmission184. However, oxygen seepage from intestinal epithelial 
cells is sensed by E. coli via FNR in vivo, and the highest oxygen concentrations exist 
nearest the epithelium188,189. Therefore, ETEC virulence gene expression is likely 
repressed in the low-oxygen lumen and is relieved when the oxygen-intolerant FNR is 




3.2.1 Controlled Human Infection Samples and RNA-sequencing 
Transcriptional adaptation to the host environment is essential for intestinal 
pathogens to colonize and cause disease.  To understand how ETEC adapts to the human 
host we characterized the transcriptome of ETEC H10407 directly in infected diarrhea 
samples taken from five different volunteers in a controlled human infection model.  The 
same inoculum was used to infect volunteers at 1.2x10^7 colony forming units each. The 
samples used in this study came from volunteers who were not prophylactically treated or 
vaccinated. These volunteers were not prescribed a fixed diet or specific rehydration 
therapy during their infection.   
     RNA extracted from stool mostly represents RNA derived from host cells, the 
native microbiome, and food waste. To specifically identify ETEC transcripts in the 
dataset, reads were trimmed to 21 bases long and mapped with 100% exact homology to 
the H10407 reference genome as previously described for similarly complex samples9.  
To be sure commensal E. coli were not influencing our RNA-sequencing data we 
measured the ratio of mapped ETEC chromosomal transcripts to transcripts that mapped 
to virulence plasmids.  If a volunteer had a prominent commensal E. coli colonization, 
which would likely produce transcripts that are highly homologous to ETEC 
chromosomal transcripts, we expected ETEC chromosomal transcripts would be over-
represented compared to ETEC-specific virulence plasmid transcripts.  We did not find 
this to be the case for any of our sequenced samples.  
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3.2.2 Environmental Oxygen Explains in vivo Virulence Gene Expression 
We determined the ETEC transcriptome directly in 5 infected diarrhea samples, 
each from different volunteers, which together as a sample group represent our in vivo 
transcriptome. 784 genes were upregulated and 637 genes were downregulated in vivo 
compared to aerobic mid-log phase growth in CFA broth (Figure 3.1a).  
Figure 3.1 ETEC gene regulation in vivo 
a. The number of upregulated or downregulated genes in infected stool compared to mid-
log phase in vitro CFA broth growth in the indicated atmospheres.  Microaerobic 
atmosphere was 85 % nitrogen, 10 % CO2, 5 % O2.  Anaerobic atmosphere was 95 % 
nitrogen, 5 % hydrogen, 0 % oxygen. b. Kegg orthology pathways statistically 
significantly (p < 0.05) represented in genes differentially regulated in vivo (fold change 
>|5| FDR p < 0.05) using a hypergeometric test.  Classical virulence factors were 
manually curated into our KEGG pathway list to be included in the analysis. In vivo 
samples represent 5 infected diarrhea samples from different human volunteers and in 




























Given the close association with the host we hypothesized classical virulence 
factor genes would be upregulated in the stool vs. in vitro growth.  Surprisingly, classical 
virulence factors were largely downregulated in stool compared to standard laboratory 
growth, including cfaD, the cfa operon, and eltAB (Figure 3.1b, Figure 3.2).   
 
Figure 3.2 Oxygen and FNR-Dependent Virulence Gene Expression in ETEC H10407 
Differentially regulated (Fold change >|3| fold, false-discovery rate corrected p-value 
<0.05) ETEC virulence genes in vivo compared to in vitro growths in different 
atmospheric oxygen concentrations.  In vitro anaerobic growth replicated the in vivo 
expression pattern of classical ETEC virulence factors. In vivo samples represent 5 
infected diarrhea samples from different human volunteers and in vitro conditions each 
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Stool is frequently used as a proxy for understanding the state of the intestinal 
environment, and a hallmark of the intestinal tract is low availability of oxygen189.  The 
difference between environmental atmospheres was a major discrepancy between our 
aerobically grown laboratory comparison and ETEC in infected stool. Despite the in vivo 
relevance of growth in limited oxygen atmospheres, we found little published research 
describing ETEC in such conditions.    
To address this, we grew biological triplicates of ETEC H10407 in 
microaerobic (85% N, 10% CO2, 5% O2) and anaerobic (95% N, 5% H, 0% O2) 
atmospheres to mid-log phase with shaking (Figure 3.3) and compared these low-oxygen 
transcriptomes to the in vivo stool transcriptomes (Figure 3.1, Figure 3.2).   
Remarkably, anaerobic growth in CFA broth completely replicated the virulence 
factor expression profile seen in vivo, with no statistically significant difference in 
expression of any classical virulence factor between the two conditions (Figure 3.2).  
This suggests understanding ETEC’s response to environmental oxygen is important for 
understanding ETEC virulence gene regulation in vivo. Notably, the expression of both 
heat stable toxin genes did not differ in vivo compared to any environmental oxygen 
concentration. This lack of statistical significance likely reflects variation in the 




Figure 3.3 Growth of ETEC H10407 in anaerobic conditions 
All growths represent 3 biological replicates grown in 5 mL CFA broth at 37°C and error 
bars represents standard error of the mean. Arabinose (0.2%) was added when indicated 
to induce expression of fnr in the pBad18-fnr complementation plasmid.   
 
 However, in controlled in vitro growths, sta2 gene expression is influenced by 
environmental oxygen while sta1 is not (Figure 3.2. Although highly homologous, the 
differences in nucleotide sequence between sta1 and sta2 ensured their expression could 
be independently determined when using our mapping parameters, and contrasting 
regulation between these two genes has been previously established in promoter::lacZ 
fusion assays129.  Overall, we found that simply altering environmental oxygen alone can 
greatly influence virulence factor expression in ETEC, with CFA, heat stable, and heat 
 




















labile toxins genes all showing altered expression in response to changes in 
environmental oxygen (Figure 3.2). 
Figure 3.4 Virulence gene expression per volunteer sample.   
The transcriptome of each volunteer sample was compared to in vitro growth in CFA 
broth under either aerobic or anaerobic atmospheres (3 biological replicates per in vitro 
condition). Classical virulence factor expression is noted per volunteer sample (numbered 
1-5) and together as an in vivo group representative of all five samples (“All”). 
Significant fold change was considered > |3| with a false discovery rate correct p value of 
<0.05 as outline in the methods.   
 
3.2.3 The FNR Transcriptional Regulator Globally Influences Virulence Factor 
Expression 
To better understand how ETEC sensing of environmental oxygen is linked with 
virulence gene expression we considered the oxygen-sensitive transcription factor FNR 
(Fumarate Nitrate reduction Regulator).  FNR is a well characterized dimeric 
transcription factor which can be directly inactivated by oxygen185,186.  In oxygenated 
conditions, an exposed Fe-S cluster in FNR is oxidized which eliminates the ability of 
 






































FNR monomers to dimerize.  The activity of antioxidant enzymes such as IscS can 
reverse this process, restoring FNR protein activity190.  In this way FNR activity is 
directly sensitive to environmental oxygen in a reversible manner.   
     We therefore hypothesized the anaerobic virulence factor repression was 
dependent on FNR activity. To test this we used recombineering to produce a Δfnr 
H10407 strain and compared the transcriptomes of three biological replicates of WT and 
Δfnr H10407 grown anaerobically to mid-log phase in CFA broth. We found a global 
increase of ETEC virulence factor expression in the Δfnr background (Figure 3.2).  
Interestingly, both sta genes were upregulated in this background, indicating that FNR 
can influence their expression despite limited changes between aerobic and anaerobic 
growth in WT bacteria. 
3.2.4 FNR Binds to Classical Virulence Factor Promoter Regions 
To examine if FNR was directly influencing virulence factor gene expression we 
used the online database Prodoric191 to determine if there were FNR binding sites in the 
upstream regions of virulence genes. We found multiple predicted FNR binding sites in 
the promoter regions of all classical virulence genes (Figures 3.5-3.8). Using 
electrophoretic mobility shift assays, we found FNR was capable of binding to the 
promoter regions of cfaD, eltA, sta1 and sta2 in vitro (Supplementary Figures 3-6). This 
is consistent with the Δfnr RNA-sequencing data and direct FNR repression of classical 
virulence genes and operons.  
     However, FNR has a well-defined role in regulating low-oxygen metabolism 
genes and therefore has a broad influence on cell physiology (Supplemental Figure 7)185.  
Consequently, it is possible that FNR is additionally altering virulence factor expression 
by influencing other known or unknown regulatory factors, although our data suggest this 
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is unlikely. Sensing of glucose concentrations via the transcription factor CRP was 
recently shown to influence transcription of promoter::lacZ fusions, and in 
Enterohemorrhagic E. coli, CRP expression increases when grown anaerobically192. 
However, we did not find differential expression of CRP (ETEC_3608) when WT ETEC 




Figure 3.5 In vitro binding of FNR to the cfaD promoter. 
a. Predicted FNR binding sites in the promoter region of cfaD using the online software 
Prodoric Virtual Footprint Promoter Analysis Version 3.0 online tool to predict E. coli 
K12 FNR binding sites. Binding sites are highlighted in red, and a score indicating how 
closely the binding sites match the FNR binding site consensus logo are given.  A perfect 
match to the consensus sequence scores a 8.93, and in vivo confirmed binding sites have 
a score range between 3.93 and 8.92 as determined by Prodoric. b. Electrophoretic 
Mobility Shift Assay (EMSA).  Purified oxygen stable FNR variant (FNRD154A)2-His6 
was mixed at the indicated amounts with PCR amplified cfaD promoter DNA (500 base 
pairs long starting at the -1 position) to test for FNR’s ability to bind to promoter DNA. A 
500bp region was used to be sure the promoter for cfaD was correctly PCR amplified 
instead of the similar promoter region for the cfaD2 homolog found elsewhere.  FNR-
DNA complexes have hindered movement in a 6% polyacrylamide DNA retardation gel 
which can be seen as a shift in the mobility of the DNA. (FNRD154A)2-His6 efficiently 
bound to the cfaD promoter and a previously characterized positive control promoter 
(ydfZ gene promoter), but not to a negative control random sequence DNA probe without 
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Figure 3.6 In vitro binding of FNR to the sta1 promoter. 
a. Predicted FNR binding sites in the promoter region of sta1 using the online software 
Prodoric Virtual Footprint Promoter Analysis Version 3.0 online tool to predict E. coli 
K12 FNR binding sites. Binding sites are highlighted in red, and a score indicating how 
closely the binding sites match the FNR binding site consensus logo are given.  A perfect 
match to the consensus sequence scores a 8.93, and in vivo confirmed binding sites have 
a score range between 3.93 and 8.92 as determined by Prodoric. b. Electrophoretic 
Mobility Shift Assay (EMSA).  Purified oxygen stable FNR variant (FNRD154A)2-His6 
was mixed at the indicated amounts with PCR amplified sta1 promoter DNA (300 base 
pairs long starting at the -1 position) to test for FNR’s ability to bind to promoter DNA.  
FNR-DNA complexes have hindered movement in a 6% polyacrylamide DNA 
retardation gel which can be seen as a shift in the mobility of the DNA. (FNRD154A)2-
His6 efficiently bound to the sta1 promoter and a previously characterized positive 
control promoter (ydfZ gene promoter), but to not the sta2 coding sequence used as a 
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Figure 3.7 In vitro binding of FNR to the sta2 promoter. 
a. Predicted FNR binding sites in the promoter region of sta2 using the online software 
Prodoric Virtual Footprint Promoter Analysis Version 3.0 online tool to predict E. coli 
K12 FNR binding sites. Binding sites are highlighted in red, and a score indicating how 
closely the binding sites match the FNR binding site consensus logo are given.  A perfect 
match to the consensus sequence scores a 8.93, and in vivo confirmed binding sites have 
a score range between 3.93 and 8.92 as determined by Prodoric. b. Electrophoretic 
Mobility Shift Assay (EMSA).  Purified oxygen stable FNR variant (FNRD154A)2-His6 
was mixed at the indicated amounts with PCR amplified sta2 promoter DNA (300 base 
pairs long starting at the -1 position) to test for FNR’s ability to bind to promoter DNA.  
FNR-DNA complexes have hindered movement in a 6% polyacrylamide DNA 
retardation gel which can be seen as a shift in the mobility of the DNA. (FNRD154A)2-
His6 efficiently bound to the sta2 promoter and a previously characterized positive 
control promoter (ydfZ gene promoter), but to not the sta2 coding sequence used as a 











Figure 3.8 In vitro binding of FNR to the eltA promoter. 
In vitro binding of FNR to the eltA promoter. a. Predicted FNR binding sites in the 
promoter region of eltA using the online software Prodoric Virtual Footprint Promoter 
Analysis Version 3.0 online tool to predict E. coli K12 FNR binding sites. Binding sites 
are highlighted in red, and a score indicating how closely the binding sites match the 
FNR binding site consensus logo are given.  A perfect match to the consensus sequence 
scores a 8.93, and in vivo confirmed binding sites have a score range between 3.93 and 
8.92 as determined by Prodoric. b. Electrophoretic Mobility Shift Assay.  Purified 
oxygen stable FNR variant (FNRD154A)2-His6 was mixed at the indicated amounts with 
PCR amplified eltA promoter DNA (300 base pairs long starting at the -1 position) to test 
for FNR’s ability to bind to promoter DNA.  FNR-DNA complexes have hindered 
movement in a 6% polyacrylamide DNA retardation gel which can be seen as a shift in 
the mobility of the DNA. (FNRD154A)2-His6 efficiently bound to the eltA promoter and a 
previously characterized positive control promoter (ydfZ gene promoter), but not to a 
negative control random sequence DNA probe without FNR binding sites. 
     Osmolarity was also shown to regulate expression of virulence promoter::lacZ 
fusions via the genome-binding protein HNS129, and HNS was significantly 
downregulated 3 fold during anaerobic growth compared to aerobic growth.  HNS has 
been shown to influence FNR and CRP binding to promoter regions185 and directly 
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12 background129. Therefore, decreased expression of HNS during anaerobic growth 
could relieve this direct repression and result in increased expression of toxin genes. 
However, only sta2 showed increased expression during anaerobic growth, and HNS 
expression was not altered in the Δfnr background compared to WT. Interestingly, 
previous work with promoter::lacZ fusions showed sta2 was also the only toxin gene 
shown to be repressed by both direct HNS-dependent repression and HNS-dependent 
inhibition of promoter activation. This stronger reliance on HNS regulation may explain 
why sta2 was the only virulence factor to have increased expression while HNS 
expression is decreased. Previous work also showed HNS repressed expression of an 
eltAB operon promoter::lacZ fusion in a K-12 background.  However, despite a 3 fold 
decrease in HNS expression during anaerobic growth, we did not see relief of this 
repression in ETEC, and our data shows the downregulation of eltAB is FNR-dependent.    
     Beyond sensing oxygen, glucose, and osmolarity, ETEC is likely integrating 
other in vivo signals to regulate virulence factor expression, including previously 
described bile and bicarbonate.  Our data shows that without additional manipulations, 
simply changing environmental oxygen influences adhesin, heat-labile, and heat-stable 
toxin gene expression, and that deletion of the oxygen-sensitive FNR transcription factor 
results in a global increase in expression of all classical virulence factor genes.  
3.2.5 FNR is a Regulator of ETEC Biofilm Formation 
Biofilm production provides bacteria protection from environmental stressors 
inside and outside of the host and has been well described in many pathogens193. In 
ETEC, biofilm production on abiotic surfaces within the homes of afflicted areas is 
correlated with seasonal ETEC epidemics84.  While characterizing ETEC in low-oxygen 
conditions we unexpectedly observed Δfnr H10407 spontaneously produced prominent 
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biofilms during anaerobic overnight growth in CFA broth at 37°C, despite vigorous 
shaking (Figure 3.9).   
Figure 3.9 FNR regulated 
biofilm formation in ETEC 
a. A picture of spontaneously 
occurring biofilm production 
when H10407 is grown in 
anaerobically at 37C with 
shaking.  Image is representative 
of more than 10 independent 
replicates. An fnr mutant 
produces more biofilm than wild 
type and this phenotype can be 
complemented by expressing the 
fnr gene from the pBad18 
plasmid in the fnr:kan mutant 
background. All depicted 
growths included 0.2 % 
arabinose for consistency with 
the induced complemented 
strain. b.  Quantification of 
ETEC biofilm formation 
exemplified in figure 5a using 
optical density readings of 
crystal violet stained biofilms as 
described in the methods section. 
All growths represent three 
independent biological replicates 
grown with 0.2 % arabinose for consistency with the induced complementation strain. 
The relative amounts of biofilm produced by various ETEC H10407 strains in the 
indicated conditions are shown compared to WT ETEC H10407 biofilm production, 
which is set as 1 as a reference.  Statistical significance determined by one-way ANOVA 
with a Tukey multiple comparison test and error bars represent the standard error of the 
mean.   
 
Quantitation of biofilm production via crystal violet staining revealed biofilm 
production increased 10 fold compared to the WT, and this phenotype was complemented 
 

























































when FNR expression was restored via expression from an inducible plasmid. More 
broadly, we found WT ETEC H10407 biofilm production increased 5 fold when grown 
anaerobically compared to aerobic growth.       
     As expected, the FNR mutant produces WT levels of biofilm when grown 
aerobically.  However, anaerobic biofilm production in the fnr mutant was increased 50 
fold compared to the WT strain grown aerobically. Together these data depict an 
interesting dynamic where ETEC can readily grow as a biofilm in an anaerobic 
environment, yet activation of FNR in this condition limits the extent of biofilm 
production.  
     Bacteria rely on a variety of mechanisms to form biofilms in response to 
changes in their environment194. To identify FNR influenced genes that contribute to 
anaerobic biofilm formation in ETEC we sought to identify upregulated genes in Δfnr 
H10407 that have been previously associated with biofilm formation.  The ETEC TibAB 
adhesin has been shown to contribute to cohesion and biofilm formation181, but 
unexpectedly, these genes are resoundingly downregulated in the Δfnr strain (Figure 3.2), 
suggesting they are unlikely to be responsible for increased biofilm formation. 
Alternatively, the main structural subunit of the Fim adhesin, fimA, was upregulated > 10 
fold. Fim-based adhesion in ETEC occurs in vivo and in vitro via a specific binding of the 
adhesive tip protein FimH to D-mannose195,196.  Therefore, exogenous D-mannose 
quenches Fim adhesive ability and disrupts biofilm formation, and sensitivity to D-
mannose is frequently used as the standard to examine Fim-dependent biofilm formation 
or cellular aglutination196–198. To see if D-mannose dependent adhesion was contributing 
to biofilm formation in Δfnr H10407 we measured biofilm production in the presence of 
increasing concentrations of D-mannose.  A concentration dependent significant decrease 
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in biofilm production was seen in the presence of D-mannose, indicating the Fim adhesin 
contributes to biofilm formation in ETEC (Figure 3.10). 
Figure 3.10 Exogenous D-mannose influence on ETEC biofilm formation 
a. Picture of ETEC biofilm formation of an fnr:kan strain grown with increasing amounts 
of D-mannose to quench activity of the fimbrial adhesin protein fimH. FimH has been 
shown previously to contribute to adhesion in ETEC.  Representative of at least 3 
independent growths.  b. Quantification of ETEC biofilm formation exemplified in figure 
Supplementary Figure 5a using optical density readings of crystal violet stained biofilms 
as described in the methods section.  All growths represent three independent biological 
replicates.  Statistical significance was determined using a one-way ANOVA test with 
tukey multiple comparisons test. Error bars represent standard error of the mean. 
3.2.6 The ETEC Transcriptome in Human Infection Samples   
Beyond virulence factors, we defined ETEC genes and pathways that were 
differentially regulated in vivo based on comparisons to different environmental oxygen 
conditions. Over one thousand genes are differentially regulated in vivo compared to the 
 
a b


























































atmospheric conditions we tested (Figure 3.1a). In vitro microaerobic growth most 
closely matched the infected stool transcriptome, while aerobic growth was the most 
different. (Figure 3.1a).   A statistical analysis of pathways that are differentially 
regulated in vivo, per environmental oxygen comparison, show virulence factor 
expression differences were highly dependent on atmospheric oxygen growth while 
chemotaxis and motility pathways were not (Figure 3.1b).  
     Despite the differences between atmospheres, 361 genes were differentially 
regulated in vivo independently of environmental oxygen changes (Figure 3.1a).  Shared 
functional roles clearly emerged while examining these data by hand (Figure 4). 
Figure 3.11 In vivo differentially expressed genes independent of atmosphere 
ETEC genes that showed differential gene expression in vivo despite the in vitro 
atmosphere comparisons (fold change > |3|, false discovery rate corrected p < 0.05) 
manually curated to highlight genes with clear functional roles. All changes in gene 
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  We found many nutrient acquisition pathways that have been important for 
intestinal colonization in small animal models are significantly differentially regulated in 
human infection samples. For example, short chain fatty acid utilization has shown to be 
crucial for colonization and/or survival of some intestinal microbes, and we see short 
chain fatty acid utilization genes in ETEC are strongly upregulated in human infection199. 
Congruently, the long-chain fatty acid import protein fadL is downregulated in vivo.  
     Similarly, striking regulation is seen in ethanolamine utilization, with 
upregulation of 9 genes involved in uptake and utilization of ethanolamine during human 
infection.  Host intestinal epithelial cell turnover releases ethanolamine into the intestinal 
lumen, and in Enterohemorrhagic E. coli and Salmonella, ethanolamine is used as a 
nitrogen source to create a competitive advantage over the microbiota to establish an 
infection200,201. These data jointly suggest ETEC may be utilizing ethanolamine during 
human infection in a similar manner.  Biotin synthesis was also upregulated in vivo, and 
in Salmonella, biotin synthesis is upregulated upon epithelial cell infection and deletion 
of the biotin synthesis gene bioB resulted in attenuated mouse colonization202.    
     Beyond nutrient acquisition genes, many genes that play a role in resistance to 
antibiotics or host factors are differentially regulated in vivo (Figure 3.11).  These include 
the mucin degradation gene eatA; fimbrial genes fimD, fimZ, mrfC and mrfD; and 
invasion/secretion associated genes invH, mrfC, and mrfD, and cexE.  Genes involved in 
multidrug efflux and resistance were also upregulated, including bile acid and 
nobobiocin/fosfomycin resistance genes mdtC/mdtG, Sulfa drug resistance genes mdtN 
and mdtO, and cefoperazone and chloramphenicol resistance genes ybhF and ybhS.   
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3.2.7 Common Gene Regulation Between UPEC and ETEC During Human 
Infection 
Few transcriptomes of bacterial pathogens in human infection samples exist.  An 
exemplary data set is that of uropathogenic E. coli (UPEC)135, where an infected urine 
sample typically represents a monoculture of urinary tract infecting bacteria.  This 
minimally complex sample enables efficient sequencing and analysis of in vivo pathogen 
transcriptomes.  Interestingly, many of the upregulated ETEC genes in infected stool we 
also upregulated in infected urine samples collected from human UPEC infections135. 
Notably, ethanolamine utilization, phosphonate utilization, taurine import, colonic acid 
synthesis, and copper efflux were all major upregulated pathways despite the differences 
between these pathogens and site of infection. As most E. coli urinary tract infections are 
established by E. coli found in fecal flora, these data suggest a common transcriptional 
response to the host across E. coli strains and infection sites in humans.   
3.3 DISCUSSION 
We examined ETEC H10407 directly in human infection samples from a 
controlled human infection model and found atmospheric oxygen influences virulence 
gene expression via the FNR transcription factor. Previously, ETEC has not been well 
characterized in low-oxygen conditions and the role of FNR in ETEC virulence and 
physiology was unknown.  
     We found CFA/I adhesin genes, including the master regulator cfaD, and the 
heat-labile toxin genes eltAB, are downregulated when ETEC is grown anaerobically.  
Consistent with FNR-dependent repression, these genes are upregulated in a Δfnr strain, 
including both heat-stable genes in H10407, sta1 and sta2.  This strikingly shows that a 
single regulator in ETEC can globally influence virulence factor expression, and in vitro, 
FNR can bind to the promoter regions of each of these genes. Similarly, anaerobic growth 
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in vitro, which represents the near zero oxygen availability status of distal small intestine 
and anaerobic large intestine, as well as bacterial overgrowth in the proximal small 
intestine, mimicked the virulence gene expression profile seen in stool samples.  
     Low oxygen availability is a hallmark of the intestinal environment, and in 
vivo, E. coli can respond to their proximity to the epithelium by sensing oxygen seepage 
from host cells188.   Together these data suggest ETEC virulence factor expression may be 
repressed by FNR in the low-oxygen lumen, and that repression is relieved when ETEC 




Illustration 3.1 A model of oxygen-dependent ETEC virulence gene regulation. 
Our study suggests ETEC directly senses environmental oxygen via the oxygen-sensitive 
transcription factor FNR which results in repressed virulence gene expression in low 
oxygen environments like the intestinal lumen.  When ETEC nears the intestinal 
epithelium, where oxygen seepage from host cells creates a zone of increased oxygen 
concentrations, FNR is inactivated which relieves virulence gene repression nearest to the 
host epithelium. Other intestinal pathogens, such as Vibrio cholerae, use a similar 
proximity-sensitive approach to regulating virulence genes within the host. In V. 
cholerae, bile has been show to repress cholera toxin expression, and similar to oxygen, 
bile exists as a gradient with the intestinal environment.  In both cases, concentrations of 
host derived factors result in repression of virulence gene expression in the lumen and 
relief of the repression when in close proximity to the target epithelium.   
 Convergent evolution across intestinal pathogens appears to have favored similar 
methods of host-cell proximity sensing.  For example, the diarrheal pathogen Vibrio 
cholerae, also senses a host cue (bile) to repress cholera toxin expression in the lumen203, 













     FNR and the ability to switch between aerobic and anaerobic metabolism is 
known to be essential for E. coli colonization204, and other intestinal pathogens also 
utilize FNR to regulate select colonization factors188.  The FNR regulon has been well 
defined in laboratory E. coli K-12 and interplays with other regulator proteins such as 
HNS and the related CRP transcriptional regulator which responds to cyclic AMP in low-
glucose conditions185.  Recent work has demonstrated the activity of both HNS and CRP 
contribute to virulence gene expression in aerobic conditions using promoter::lacZ fusion 
assays in K-12 background129, and certainly, all may play a role in the low-glucose, low-
oxygen environment of the intestinal tract. 
     Beyond classical virulence factor expression changes, we found many cellular 
processes were differentially regulated in vivo.  These include ethanolamine utilization, 
short chain fatty acid utilization, phosphonate utilization, and copper efflux.  Notably, 
previous work demonstrated these same processes were also upregulated in human UPEC 
infections.  Further, all of these have been shown to contribute to fitness in small animal 
models of infection, and here we found they respond transcriptionally to the human host 
during ETEC infection. 
     Besides offering insight into ETEC gene regulation in vivo, these data have 
implications for studies that examine ETEC virulence factor expression in collected 
infected samples205,206. Our data suggest stool samples should be maintained or preserved 
with consideration for atmospheric oxygen to be sure differences in virulence factor 
expression between samples or strains cannot be attributed to differences in oxygen 
exposure after collection.  
     During our characterization of ETEC in low-oxygen conditions we noticed an 
oxygen-sensitive biofilm production phenotype.  Only a few studies have investigated 
ETEC biofilm formation, although ETEC biofilms in home water reservoirs in afflicted 
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areas are correlated with seasonal epidemics84.  Here we show robust ETEC biofilms can 
be produced overnight when Δfnr H10407 is grown anaerobically in CFA media. 
Together, this demonstrates an interesting FNR-dependent link between ETEC’s lifestyle 
in the environment and in the host.  This study represents the joint efforts between 





Chapter 4: Discussions on Bacterial Adaptation During Human 
Infections 
4.1 INSIGHTS INTO C. JEJUNI INFECTION IN HUMANS AND FUTURE WORK 
The work described in Chapter 2 has significantly advanced our understanding of 
C. jejuni infections in humans. First, C. jejuni infections are associated with an 
assortment of possible symptoms, each with seemingly unpredictable severity between 
patients.  Previously reported controlled human infection models revealed that even when 
a group of volunteers are infected from the same inoculum at the same time the severity 
of symptomatic disease can markedly vary between volunteers. 
 Considering C. jejuni’s phase variable nature, one hypothesis to explain disease 
severity discrepancies between humans is that more virulent genetic backgrounds take 
hold in particular patients by chance.  This could be due to either 1) genetic drift of a 
more virulent phenotype 2) chance bottleneck colonization52 by bacteria with a differing 
virulence between volunteers or 3) chance fluctuations in phase variant frequencies of 
virulence genes in vivo that result in differing symptomatic disease. This hypothesis 
therefore focuses on bacterial contributions to disease severity in humans.  An alternative 
hypothesis is that host factors dictate symptom severity.  In this case, since all volunteers 
are infected from the same inoculum, the symptom variability between patients could 
result from 1) differing immune responses per host i.e. a stronger intestinal inflammatory 
response may be more likely to produce bloody diarrhea or 2) differing commensal gut 
flora that influence C. jejuni’s ability to induce symptoms or 3) yet to be identified non-
immune factors.  
Our data clearly demonstrate there is no detectable colonization bottleneck in 
humans, as a very consistent genetic selection pressure was identified even on the day of 
inoculation.  Had bottlenecking been a major issue, seemingly random genetic variations 
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would have been seen colonizing different individuals, as only some genetic backgrounds 
would be able to pass the colonization bottleneck by chance.  Further, because very 
similar genetic variations were identified across patients and throughout the entirety of 
acute infection, there is little evidence to suggest genetic drift or more virulent 
phenotypes could produce more severe symptoms.  Remarkably, there was no particular 
genetic variation (phase variation or otherwise) that was statistically significantly 
associated with samples from volunteers who experienced severe disease.  This strongly 
suggests host factors, and not differences between infection populations, dictate disease 
severity.  Future work should examine if differences between the commensal microbiome 
populations are associated with volunteers with severe disease.  
It is also possible that the bacteria that are shed from the host are not 
representative of the genotypes that actively induce symptomatic disease. For instance, if 
invasive bacteria are solely responsible for symptoms, they may not be shed from the 
host, and therefore we are not identifying them be screening post-infection isolates. This 
possibility is unlikely during acute infection, as the current literature suggestions invasion 
is a low-frequency event, so genotypes that promote invasion should still be detected in 
shed bacteria.   
Another potential limitation to this study was the requirement to use pooled 
infection isolate populations.  Infected feces were streaked onto solid medium and single 
colony isolates were collected and pooled together (per patient sample) for genomic 
sequencing.  This enabled efficient sample processing and analysis. However, it makes it 
difficult to determine the exact genetic variations that existed in a single genome.  
Knowing which genetic variants were identified within a single genome would elucidate 
potentially synergistic variants. 
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Although no genotypes are associated with symptom severity, variability in 11 
genetic loci were associated with persistent infections in humans.  This is the first 
description of factors that contribute to recrudescent infections in humans, and unlike 
symptom severity, there are clear bacteria-specific factors associated with recrudescence.  
Importantly, humans are the only model system we have to accurately represent 
recrudescent infections, as small animal models are routinely cured with antibiotics while 
humans can relapse despite what initially appears to be effective antibiotic treatment. It is 
likely not a coincidence that phase activation of the cipA gene, a known in vitro invasin,  
is associated with persistent bacteria.  It strongly suggests that persistent C. jejuni are 
invasive, and it is attractive to speculate that enhanced invasive ability promotes C. jejuni 
to better evade the host immune response and antibiotic exposure. There is also strong 
selection of flagellar glycosylation genes in persistent bacteria.  Although O-linked 
glycosylation genes have been characterized in C. jejuni, their functional role in vivo is 
unclear.  Likely scenarios include changing glycosylation patterns helps avoid immune 
detection of the flagella, and since flagella are associated with motility, attachment, and 
invasion, phase variation of O-linked glycosylation genes may also contribute to 
invasion. 
Finally, the most surprising genetic association with C. jejuni recrudescence is 
truncation of the CmeR bile-sensing transcription factor.  Bile-sensing is a hallmark of 
intestinal pathogens, and losing the ability to sense changes in environmental bile 
concentrations is a surprising phenotype for an intestinal pathogen. The truncations 
identified eliminated the dimerization domain that is essential for CmeR’s ability to bind 
DNA and repress its target promoters.  Therefore, truncation would lead to constitutively 
expression of the CmeR regulon, which includes a bile-acid efflux pump.  Future work 
should determine the extract to which this change in regulon expression influences C. 
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jejuni’s ability to survive bile acid stress.  It is worth noting that the CmeR genetic 
variations we identified were in two different non-phase variable loci and occurred in 1/3 
of relapse infections tested. These non-phase variable mutations naturally occur at a very 
low frequency, but given the high frequency they existed in their respective relapse 
infection populations, they likely conferred a significant fitness benefit to persistence in 
vivo.     
We also utilized samples from a non-human primate infection model to further 
verify genetic selection pressures C. jejuni experiences in primates.  Strain CG8421 is not 
adapted to the new world monkey A. nancymaae and, therefore, requires a higher 
inoculation dose to induce symptomatic disease.  However, future work should examine 
if post-infection isolates from this this experiment require a lower infectious dose to 
induce symptoms.  This would suggest the genetic variations we identified do indeed 
increase success in the host.  Further, there are currently no non-human infection models 
to study recrudescent infections.  Future work could examine if infecting A. nancymaae 
with an inoculum enriched for cipA “on” bacteria results in recrudescent infection.  This 
would 1) provide greater support for cipA’s role in persistence and 2) establish an 
additional model for studying recrudescent C. jejuni infections. Finally, the precise 
structure of the flagellar modification produced by CipA should be determined and 
evaluated for its potential to be used as an antigen in future vaccine preparations.  
Perhaps immunizing against CipA modification may lower the incidence of persistent C. 
jejuni human infections.  
4.2 A SIMPLER MODEL OF ETEC VIRULENCE GENE REGULATION 
The work presented in Chapter 3 presents a clear, unified regulation scheme for 
ETEC virulence gene regulation. For the first time, a single environmental factor, and 
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corresponding transcriptional regulator, was show to influence every classical virulence 
gene in ETEC.  This regulatory factor, oxygen, further provides a simplistic view 
virulence gene expression: as ETEC approaches the oxygen rich zone nearest to the host 
epithelium, virulence factor expression is increased. 
However, the amount of genetic diversity in ETEC virulence factors is staggering, 
and it is reasonable that not every ETEC isolate will behave like the prototypical H10407 
strain used in this work.  For instance, oxygen regulation of ST is irrelevant in an ETEC 
strain that does not harbor ST, and without ST, there may be less pressure to coordinate 
remaining virulence factors via a single environmental signal.  Promoter analysis in 
diverse ETEC strains could be used to identify putative FNR binding sites to provide 
more insight, and EMSA assays were straight forward in determining FNR’s ability to 
bind to such promoters.   
FNR is a well-known virulence regulator in other enteric pathogens. Therefore, 
discovering its role in ETEC virulence gene regulation is not a controversial mechanism 
that requires unusually burdensome experimentation.  However, future work examining 
the role of FNR in additional ETEC strains will be valuable and appreciated.  
Particularly, the use of chromatin immunoprecipitation of FNR to identify its binding 
sites in vivo (ChIP-seq) is a clear next step.  ChIP-seq has been used to characterize the 
FNR regulon in laboratory K-12 E. coli and this data set can be used as a positive control  
to verify an ETEC ChIP-seq experiment identified known chromosomal FNR binding 
sites in E. coli – for instance, in the promoter region of the ydfZ gene which contains a 
conserved FNR binding site sequence and used as a positive control in the EMSA assays 
prestend in Chapter 3.  ChIP-seq data would also be beneficial to confirm that FNR is 
displacing HNS and/or CRP binding during anaerobic growth.   
 88 
Finally, the new FNR and oxygen-dependent regulation scheme paired with 
within-human expression data can reveal genes that are co-expressed with ETEC 
virulence factors.  For instance, identifying surface exposed gene products (which would 
be accessible to the immune system or small molecule therapies) that are 1) highly 
expressed in concert with virulence genes in vivo and 2) are well conserved across ETEC 
strains, may identify new proteins that could potentially be used in future ETEC vaccines.  
It is important to note that major virulence factors, such as adhesins, are highly variable 
across ETEC strains, and therefore more highly conserved targets (which still share 
expression patterns with known virulence factors) could prove useful in making a broadly 
protecting ETEC vaccine.    
4.3 CREATING A FRAMEWORK FOR FUTURE CLINICAL TRIALS 
The work presented in Chapters 2 and 3 relied on preserved human infection 
samples taken from controlled human challenge models.  These challenges are used to 
establish minimum infectious dosages for pathogens, characterize host symptoms and 
immune responses, and then later to test the efficacies of new potential therapies.   
Typically, the focus of these studies are clinician-driven care for volunteers and 
immunological studies on the host response to the infection and the treatment.  Here we 
have expanded the scope of these trials to include comprehensive analysis of the 
pathogen itself.  The most striking benefit to studying pathogens in controlled human 
infections versus community infections is the inoculum consistency.  Every volunteer 
ingests a portion of a single inoculum, and therefore confounding factors due to wildtype 
strain variation, differences in inoculum dosages, and differences in time-from-exposure 
between humans can be eliminated.   
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As detailed in Chapter 5, this required efforts to training personnel to collect and 
preserve both inoculum and infection isolate populations and additional microbiologists 
to analyze these samples. However, given the data generated from this work and 
presented in Chapters 2 and 3, the effort provided invaluable insight into human infection 
that would have otherwise gone unrealized.  Future clinical trials should consider using a 
similar sample collection and analysis framework to gain similar useful insights.  
 Importantly, future trials should integrate the immunological and clinical 
prognoses observations with observed changes in the pathogen.  For instance, before 
infection, feces samples could be collected to detect changes in the microbiome before, 
during, and after infection. Similarly, if a volunteer required intervention, such as 
intravenous rehydration therapy, special attention could be given to examining how the 
pathogen adapted in vivo before and after the therapy.  Although this approach could be 
perused after a trial has completed by synthesizing available data, the most appropriate 
samples may not have been collected during the trial. For example, if only one sample 
per volunteer is preserved per day, a sample collected in the morning may not be 
representative of the disease state 18 hour later that required clinical intervention.  
Therefore, frequent and dynamic sample collection, conducted while considering the 
disease state of each volunteer, could be a valuable change in future work.  
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Chapter 5: Experimental Methods  
5.1 EXPERIMENTAL METHODS USED IN CHAPTER 2 
5.1.1 C. jejuni Infected Human Feces Sample Preparation for RNA-Sequencing 
Campylobacter jejuni strain CG8421 infected diarrhea was weighed and added 
1:1 in RNA Later reagent as quickly as possible after it was produced and frozen at -
80°C. Samples came from volunteers who were not receiving antibiotics and therefore 
represent untreated infections. Preserved samples were thawed on ice and total RNA 
extracted via Trizol-chloroform phase separation.  DNA was removed (Turbo DNA-free 
DNAse kit, Ambion), rRNA depleted (Ribo-Zero human and bacterial rRNA removal 
kits, Illumina), and libraries built for Illumina Sequencing (Ultra Directional RNA 
Library Prep Kit for Illumina, New England Biolabs). 
 
5.1.2 In vitro C. jejuni Sample Preparation for RNA Sequencing 
Campylobacter jejuni strain CG8421 was grown at 37°C in a microaerobic 
atmosphere (85% nitrogren, 10% carbon dioxide, 5% oxygen) in a Coy Laboratories 
atmosphere controlled chamber. For RNA-seq of samples grown on agar plates: Mueller-
Hinton agar or 5 percent sheep blood agar plates were streaked in triplicate from a frozen 
stock of C. jejuni strain CG8421. >10 Colonies from these plates were re-streaked on 
fresh plates and mid-log phase bacteria were harvested and suspended in Trizol reagent 
for RNA extraction. For RNA-seq of samples grown in liquid broth: 5 mL aliquots of 
Mueller-Hinton broth were equilibrated in the microaerobic chamber for 24 hours before 
being inoculated and were grown with shaking.  First, Mueller-Hinton agar plates were 
steaked in triplicate from a frozen stock of C. jejuni strain CG8421. Colonies from these 
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plates were used to inoculate equilibrated broth and grown with shaking to stationary 
phase.  These cultures were then used to inoculate freshly equilibrated Mueller-Hinton 
broth aliquots, which were grown with shaking until mid-log phase.  Bacteria were then 
harvested via centrifugation and resuspended in Trizol reagent for immediate RNA 
extraction. Extracted RNA was DNAse treated (Turbo DNA Free DNAse Kit, Ambion), 
rRNA was removed (Ribo-Zero Bacterial rRNA Removal Kit, Illumina) and the samples 
were prepared for Illumina Hiseq using the TruSeq Stranded mRNA Library Kit 
(Illumina). 
 
5.1.3 Illumina RNA Sequencing and Analysis   
For RNA sequencing of samples from infected human feces, three RNA libraries 
built from the infected feces samples of different volunteers were sequenced using 
Illumina Hiseq Single-End 50bp reads.  Approximately 13 billion reads were obtained in 
total across all three samples. Using CLC Genomics Workbench software, reads were 
trimmed to 21bp and aligned to the CG8421 published reference genome using 100 
percent exact homology match mapping parameters.  At least 3 million reads mapped to 
the reference genome per sample. For in vitro samples, RNA libraries were sequenced 
and aligned in an identical manner, with at least 15 million reads mapping to the 
reference genome per sample.  To determine differential expression between samples, 
Reads Per Kilobase per Million reads (RPKM) values were determined for each gene, 
normalized by quintile, and then were used in a Baggerley’s test to determine the 
weighted proportions fold change between groups of biological replicates (all groups 
were in triplicate) with a false discovery rate corrected (FDR) p-value.  Fold changes ≥ |3| 
with a FDR p-value of ≤ 0.05 were considered significant. Annotation of differentially 
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regulated CG8421 genes was made by considering the annotations of homologous genes 
in strains 81-176 and 11168 as determined by NCBI’s online blastp suite. Additional 
functional annotations were made after considering published literature, using NCBI’s 
PubMed literature search online.   Comparison of the CG8421 transcriptome in human 
feces to the C. jejuni 81-176 transcriptome in the chicken cecum was made by using the 
published list of expression fold changes per 81-176 gene in the chicken cecum as 
described in Sup. Table 2. Both datasets use mid-log phase microaerobic growth in 
Mueller-Hinton broth as the reference transcriptome.  We compared the list of 
differentially regulated CG8421 genes in human feces (>|3| fold, <0.05 FDR p-value) to 
the list of differentially regulated 81-176 genes (>|3| fold, < 0.05 adjusted p-value) in the 
chicken cecum.  Only genes with a homolog in both strains (as determined by similarity 
of predicted amino acid sequence) were included in the comparison.   
 
5.1.4 Human Infection and Inoculum Preservation 
Samples were obtained from a previously described61 controlled human infection 
model (ClinicalTrials.gov Identifier NCT02280044, Navy Medical Research Center IRB 
NMRC.2014.0013, and Western Institutional Review Board study number WIRB 
1147996).  Volunteers were healthy adults recruited from the mid-Atlantic area, signed 
informed consent prior to participating in the study, and allowed for all future use of the 
samples obtained during the study.  Volunteers who were admitted to the inpatient 
facility at Johns Hopkins University Center for Immunization Research for the study had 
ages ranging from 18-50 years old (median 30), normal stool patterns, were not using 
antidiarrheal or antacid therapy, and had no history of clinically significant diseases. 
Subjects with a history of Campylobacter exposure, a personal and/or family history of 
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Guillain-Barre syndrome and/or inflammatory arthritis, were positive for HLA-B27, or 
whose serum immunoglobulin A titer to CG8421 glycine extract was greater than 1:4000 
were excluded from the study. Admitted volunteers were inoculated on Day 0 with a C. 
jejuni CG8421 liquid inoculum that was generated using Good Manufacturing Processing 
(GMP) and kept on ice.  The inoculum is derived from Mueller-Hinton agar plate 
growths that are suspended in phosphate buffered saline, and therefore has complex 
standing genetic variation (detailed in Sup. Table 3) and is not derived from a single 
colony. This resuspension method was used for the Aotus nancumaae inoculum 
preparation as well.  Immediately prior to inoculation, the PBS resuspension human 
inoculum (target concentration of 5x105 colony forming units per ml (CFU/mL) was 
diluted in sodium bicarbonate buffer (NaHCO3) to neutralize stomach acids and ingested. 
After the last patient was inoculated, a portion of the remaining inoculum was used to 
verify the infection dosage via growth and colony enumeration on Campylobacter CVA 
(cefoperazone, vancomycin, and amphotericin B) agar (dosage was 1.7x105 CFU) and 
another portion was frozen at -80°C to later be used for genomic sequencing. 
 
5.1.5 Human Infection Isolate Collection/Preservation  
Campylobacter isolation from infected feces was performed as previously 
described61. Briefly, infected feces were diluted and temporarily incubated in 
thioglycollate broth, plated on selective Campylobacter media, and incubated in a 
microaerobic atmosphere at 37C.  Colonies on these primary isolation plates were 
screened by eye and all putative C. jejuni colonies were collected and pooled together in 
glycerol media per sample and frozen at -20°C. An effort was made to collect at least 10 
colonies per sample, and samples with insufficient amounts of C. jejuni isolates were 
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identified during analysis of the sample genomes (samples with less than 50x coverage of 
the genome) and removed from the study.  
 
5.1.6 Genomic Sequencing  
The frozen inoculum and isolate samples were thawed on ice, genomic DNA was 
extracted (Easy DNA Kit, Invitrogen) from each sample, followed by processing for 
Illumina NextSeq Single-Read sequencing. All genome analysis was preformed using 
CLC Genomics Workbench.  Reads were aligned to the CG8421 reference genome for 
each isolate population. Only isolate population samples with at least 50x coverage of the 
CG8421 genome were included for genomic variant analysis. These samples averaged 
>1000x genome coverage (Fig. 2.3).   
 
5.1.7 Genomic Variant Calling 
Mapped reads were locally realigned and genomic variations compared to the 
reference genome were identified using a no ploidy assumption low frequency variant 
detection method. For the highest quality data we manually removed clear false positive 
variant calls, such as SNPs called in extensive pileups of single reads or in regions of 
unreliable coverage. By calling variants that occurred in at least 1 percent of any sample 
population, we identified over 600 genomic variants across all samples. This list of 
variants, including their frequency in the population, per sample, is provided in Sup. 
Table 1. To enrich this list for meaningful variants that may impact the human disease 
state, we aimed to identify genome variants that had major changes in frequency between 
the inoculum and isolate populations, such as a minority variant in the inoculum 
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becoming a majority variant in an infection isolate population.  By defining a variant as a 
mutation that occurred in at least 25 percent of a sample population, and identifying 
variants that differed between the inoculum and an isolate population, we achieved this 
goal (Fig 1.3). For example, using this approach, variants that were only called in an 
isolate population(s) on average had a 12-fold increase in frequency between the 
inoculum and the infection isolate populations (Fig. 2.4).  These variants represented a 
minority of the inoculum population (~5 percent on average), but a majority in the isolate 
population (~60 percent on average across samples) (Fig. 2.4).  These variants were used 
in the analyses throughout the study.   
 
5.1.8 Genomic Variant Analysis 
Our variant calling procedure identified 48 genomic variants with major changes 
in frequency between the inoculum and least one isolate population. Based on variant 
location in the published annotated CG8421 genome, these variants likely affect ~30 
annotated genes. In many cases, different variants across samples had an equivalent 
predicted affect on the same gene (such as an insertion or deletion induced frameshift at 
the same location in the same gene) and this is shown for each variant in Sup Table 1d. 
To incorporate these shared variant affects into our analysis, we manually refined the 
variant lists to reflect the genes affected by each variant (Illustration 2.3, Step 5), so that 
different variants with the same affects were considered as equivalent.   This enabled us 
to determine if variation in a particular gene was associated with the human disease state 
(Illustration 2.3, Step 6) such as if a variation in a particular gene is associated with 
relapse isolate populations compared to primary infection isolate populations. To do this, 
we preformed Fisher’s exact test with a false discovery rate (FDR) corrected p-value in 
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CLC Genomics Workbench to compare variants between sample groups. The Microbial 
Genomics module of CLC Genomics Workbench was used to generate the SNP-tree seen 
in Figure 4a using the work done by Kass et al207. Briefly, the tree visually represents 
how similar genomic variations are between samples.  The closer two samples are to each 
other, the more similar the genomic variations. When examining genomic variants 
between samples, different variant alleles at the same genomic location are scored as 
different variants. Other statistical tests used to compare variant frequencies were 
performed in the statistics and graphing software Prism 6 and are noted in the appropriate 
figure legends.  
 
5.1.9 Aotus nancymaae Infection, Isolate Collection, and Analysis 
The Aotus nancymaae infection protocol was approved by the Naval Medical 
Research Unit-6 Institutional Animal Care and Use Committee (IACUC approval number 
NAMRU6-16-03) in compliance with all applicable Federal regulations governing the 
protection of animals in research. Aotus nancymaae monkeys were infected as described 
previously62,208 with a single C. jejuni CG8421 liquid inoculum that was harvested from 
Mueller-Hinton agar plates and resuspended in PBS similarly to harvesting bacteria for 
the human inoculum. Animals were treated with rantidine and CeraVacx to neutralize 
stomach acid and were anesthetized with ketamine intramuscularly.  Animals were 
inoculated with 5 x 1011 bacteria in 5 ml of PBS orogastrically for infection and a portion 
of the inoculum was frozen at -80°C for preservation and genomic sequencing. C. jejuni 
infected diarrhea was plated on Campylobacter selective media as previously 
described62,208 and isolates were collected and pooled per sample, processed for 
sequencing, and data analyzed in a parallel manner as described for the human infection 
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isolate population samples. After genomic sequencing, 12 diarrheal samples from 5 
monkeys covering 8 days of infection had high enough C. jejuni isolate counts to be 
included in this study (as determined by CG8421 genome coverage), as indicated in Sup. 
Table 1, and were produced by male and female monkeys with a median age of 14 
months as noted in Table 1. The Aotus inoculum was prepared independently of the 
human inoculum, and similarly, is not derived from a single colony. This accounts for 
differences in standing genetic variation between the two inoculums. Therefore, the Aotus 
infection isolate population genomes were compared to the Aotus inoculum during 
genetic analysis of the Aotus samples. The samples used in this study were selected from 
an Aotus nancymaae infection preformed as a randomized controlled immunization and 
C. jejuni CG8421 challenge model. Power calculations were used to determine the 
appropriate number of animals to be used in that preventative treatment investigation 
model. To be consistent with our human isolate data, we only used samples if: 1) the 
sample represented symptomatic disease (diarrhea), 2) the sample was produced by an 
animal that did not receive therapy before or at the time the sample was produced and 3) 
genomic sequencing yielded sufficient coverage of the C. jejuni CG8421 genome for 
genetic analysis. Therefore, it was necessary that choosing samples for use in our study 
be performed in a nonblinded manner.  
 
5.1.10 Cj0617/618 Flagellin Mobility Shift Assay 
The following genetic studies were performed on strain 81-176 because strain 
GC8421 is not amenable to genetic analyses.  The homopolymeric tract in Cj0617/618 
was repaired as previously described55.  Briefly, the genes were PCR amplified and 
cloned behind a sigma28 promoter.  The G tract was repaired such that the two genes 
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were fused into a single open reading frame, and the codons were modified to introduce 
silent changes that removed the homopolymeric tract by Quick Change mutagenesis 




The repaired gene and a kanamycin resistance cassette were introduced into the 
arylsulfatase gene of 81-176.  Purified flagellins were separated using ampholytes 
ranging from 4-6 (Biolyte 4/6; BioRad) as previously described209.  IEF protein markers 
were purchased from Serva. 
 
5.1.11 Data Availability  
All genomic and RNA sequencing data used in this study have been deposited in 
the NCBR sequence read archive under Bioproject PRJNA392448. 
 
5.2 EXPERIMENTAL METHODS USED IN CHAPTER 3 
5.2.1 ETEC Human Infection Model  
Volunteers for Enterotoxigenic E. coli H10407 infection (ClinicalTrials.gov 
Identifier NCT01922856, Navy Medical Research Center IRB NMRC.2013.0011) were 
healthy adults from the mid-Atlantic region of the United States. Volunteers signed 
informed consent forms before participating and allowed for future use of samples 
produced during the study.  Volunteers were either male or female between 18-50 years 
of age, were in general good health, without significant medical history or previous 
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exposure to ETEC or Vibrio cholerae, did not have an abnormal stool patterns, and did 
not regularly use laxatives or antacids. On the day of the challenge, volunteers drank 
120mL of bicarbonate buffer, followed by 30mL of bicarbonate buffer containing 1.2x107 
CFU of virulent ETEC H10407.  Inoculum bacteria were initial grown overnight at 37°C 
on 3 CFA agar plates supplemented with bile salt, and then suspended in PBS.  PBS 
resuspension was kept on ice until being incorporated into the final bicarbonate buffer 
inoculum given to volunteers.  Inoculum concentration was initially estimated via optical 
density 600nm readings on the day of the challenge and then confirmed using colony 
forming unit enumeration on LB agar plates after overnight incubation at 37°C.  
 
5.2.2 Infected Sample Preparation for RNA-Sequencing 
ETEC H10407 infected diarrhea was weighed and added 1:1 in RNA later reagent 
as quickly as possible after production and frozen at -80C. We only worked with infected 
diarrhea samples from volunteers who were not vaccinated against ETEC, were not 
receiving antibiotic treatment at the time of production, did not have a restricted diet, and 
were not receiving prescribed rehydration therapy.  Preserved infected samples were 
thawed in a secondary container on ice and total RNA was extracted via Trizol-
chloroform phase separation.  DNA was removed (Turbo DNA-free DNAse kit, Ambion) 
and rRNA was depleted (Ribo-Zero human and bacterial rRNA removal kits, Illumina).  
Libraries were built for Illumina next-generation sequencing (Ultra Direcitonal RNA 
Library Prep Kit for Illumina, New England Biolabs).   
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5.2.3 In vitro ETEC Sample Preparation for RNA-Sequencing 
     Enterotoxigenic E. coli strain H10407 was grown at 37°C in either standard 
aerobic atmospheric conditions, or in a in a Coy Laboratories atmosphere controlled 
chamber for low-oxygen growths.  The microaerobic atmosphere used was 85% nitrogen, 
10% carbon dioxide, and 5% oxygen, while the anaerobic atmosphere was 85% nitrogen, 
10% carbon dioxide, 5% hydrogen.  For bacterial growth, CFA agar plates were streaked 
from a frozen stock of ETEC H10407 and grown overnight at 37°C in the indicated 
atmosphere.  Single colonies were used to inoculate 5 mL aliquots of CFA broth in 
triplicate and grown with shaking in the indicated atmosphere.  For low-oxygen 
atmosphere growths, CFA broth aliquots were equilibrated with the atmosphere overnight 
with shaking at 37°C prior to inoculation.  For RNA-sequencing, all cultures were grown 
in triplicate to mid-log phase in the respective atmosphere, harvested via centrifugation 
within the respective atmosphere, and resuspended in Trizol reagent within the respective 
atmosphere for immediate RNA extraction.  DNA was then removed (Turbo DNA Free 
DNAse Kit, Ambion), rRNA was removed (Ribo-Zero Bacterial rRNA removal Kit, 
Illumina) and the samples were prepared for Illumina sequencing using the TruSeq 
Stranded mRNA Library Kit (Illumina).   
 
5.2.4 Illumina RNA-sequencing and Analysis 
Infected samples are complex and ETEC RNA represents a small portion of total 
sample RNA.  To identify ETEC-specific transcripts we trimmed sample reads to 21 base 
pairs in length and then mapped them with 100% exact sequence homology to the ETEC 
H10407 reference genome using CLC Genomics Workbench software, as has been 
previously described with similarly complex samples9. At least 3 million reads mapped to 
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the H10407 reference genome per sample. 5 infected diarrhea samples each from 
different volunteers were sequenced and analyzed individually, and then together as a 
group represented our in vivo condition for analysis.  For in vitro samples, reads were 
trimmed and mapped in an identical manner, with at least 15 million reads mapping to the 
reference genome, and all in vitro conditions represent a group of 3 biological replicates.  
     CLC Genomics WorkBench (Qiagen) was used to to determine differential 
gene expression fold changess between conditions and a false discovery rate corrected 
(FDR) p-value was used to determine statistically significance. We considered a 
significant change in expression between groups to be a weighted proportions fold 
change > |3| with a FDR p-value of <0.05. 
    To determine if any native commensal E. coli were influencing the mapped 
reads from in vivo samples, we compared the ratio of chromosomally mapped reads vs 
reads mapped to ETEC-specific virulence plasmids.  We assumed commensal E. coli 
genomes would share extensive homology to the ETEC chromosome, and therefore if 
commensal E. coli were influential, chromosomal reads would be over-represented 
compared to reads mapped to ETEC virulence plasmids.  We did not find chromosomal 
reads to be over-represented, and therefore we did not see a large representation of non-
ETEC reads mapping to the ETEC reference genome.  
 
5.2.5 ETEC Recombineering and Complementation 
     To generate a knockout of fnr in ETEC H10407 lambda red-mediated gene 
replacement was used as previously described in E. coli210.  Briefly, the kanamycin 
cassette from the pkD4 plasmid was PCR amplified with 50 basepair flanking regions 
which were homologous to the immediate up and downstream regions of the 
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chromosomally encoded fnr gene.  This linear PCR product was cleaned using the 
QIAquick PCR Purification Kit and electroporated into H10407 containing the pkD46 
plasmid, which produces the lambda red recombinase, and mediates the homologous 
recombination of the fnr locus with linear PCR product.  Recombinant bacteria were 
selected for on kanamycin LB agar and fnr:kan mutants were verified by PCR, sanger 
sequencing, and by observing an expected growth defect in low-oxygen conditions 
compared to WT (Supplementary Figure 1).  fnr:kan was maintained on agar plates and 
in liquid medium in the presence of kanamycin.   
     The fnr complementation plasmid (pBad18-fnr) is an arabinose inducible 
pBad18 plasmid carrying a chloramphenicol resistance cassette and was built using 
Gibson assembly. pBad18-fnr was electroporated into the fnr:kan H10407 genetic 
background. Complementation was determined by PCR verification of the plasmid, 
alongside rescue of the fnr:kan anaerobic growth defect (Fig. 3.3) as well as rescue of the 
increased biofilm formation phenotype (Fig. 3.9). fnr:kan pBad18-fnr was maintained in 
the presence of kanamycin and chloramphenicol and with 0.2% arabinose when 
indicated.    
 
5.2.6 Electrophoretic Mobility Shift Assays (EMSA) 
     FNR activity is sensitive to oxygen, making most standard in vitro assays, 
including purification, difficult.  To address this, we used a well characterized FNR 
variant, (FNRD154A)2, which is physically linked as an active dimer and is therefore 
active in aerobic environments.  This variant has been validated for use in EMSA assays, 
and purified (FNRD154A)2-His6 was generously provided to us by Lisa Kay Nolan and 
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prepared as previously described198. Purified protein was stored at -80C in binding buffer 
(20mM Tris HCL, 50mM NaCl, 40mM EDTA, 4mM DTT, 10% glycerol, pH 6.8).    
    All assays were carried out as previously described198 by mixing increasing 
amounts of (FNRD154A)2-His6 with the PCR amplified promoter regions of virulence 
factor genes as the DNA probe.  PCR amplified promoter regions were size-selected 
using a Zymoclean DNA Gel Recovery kit (Zymogen) and then cleaned using the DNA 
Clean and Concentrator kit (Zymogen).  Binding reactions of (FNRD154A)2-His6  to 
DNA probes were performed in binding buffer mentioned above with 0.5mg/ml bovine 
serum albumin, in 25 uL total volume, at 37°C for 30 minutes. Concentrations of protein 
and probe used are detailed per assay in supplementary figures 3-6 for clarity.    Reaction 
mixtures were run in a 6% polyacrylamide DNA retardation gel (Invitrogen) in 0.5 TBE 
buffer (Invitrogen) at 200V for 45 minutes and gels were stained with ethidium bromide 
in 0.5 TBE buffer for 10 minutes at room temperature before being exposed to ultraviolet 
light for imaging.  
 
5.2.7 Biofilm Production and Measurement 
     We found ETEC H10407 spontaneously grew biofilms on glass test tubes 
when grown anaerobically at 37C in 5 mL of CFA broth with vigorous shaking.  To 
quantitate biofilm production, growth media was removed from test tubes using a 
serological pipette and then 0.1% filter sterilized crystal violet stain was added to the tube 
to completely submerge the biofilm and incubated for 20 minutes at room temperature.  
The stain was removed via serological pipette, and then stained biofilms were carefully 
washed at least 3 times with phosphate buffered saline to be sure there was no residual 
stain remaining in the tube. Stained and washed biofilms were air dried at room 
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temperature for 30 minutes and then solubilized in 95% ethanol via pipetting. Dilutions 
of the solubilized stain were pipetted into a 96-well clear bottom plate, and then the 
optical density 595nm was determined for each sample using 95% ethanol as a blank.  All 
conditions were tested in biological triplicate.  Statistical significance was determined 
across samples using a one-way ANOVA followed by Tukey’s multiple comparison test 
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